[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 11320
1. Leach P, Abou-Zeid AH, Kearney T, Davis J, Trainer PJ, Gnanalingham KK: Endoscopic transsphenoidal pituitary surgery: evidence of an operative learning curve. Neurosurgery; 2010 Nov;67(5):1205-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: There were 67 patients (54%) with nonfunctioning adenomas, 22 (18%) with acromegaly, and 10 (8%) with Cushing's disease.
  • Between study periods 1 and 2, there was a decrease in the mean duration of surgery for nonfunctioning adenomas (from 120 minutes to 91 minutes; P < .01).
  • This learning effect was not apparent for functioning adenomas, the surgery for which also took longer to perform.
  • There were nonsignificant trends toward improved endocrine remission rates for patients with Cushing's disease (from 50% to 83%), but operative complications, notably the rates of hypopituitarism, did not change.

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20871457.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


2. Mantovani G, Lania AG, Spada A: GNAS imprinting and pituitary tumors. Mol Cell Endocrinol; 2010 Sep 15;326(1-2):15-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Accordingly, mutations of the alpha subunit of the stimulatory G protein gene (GNAS) leading to the constitutive activation of adenylyl cyclase (the so-called gsp oncogene) have been found in a significant proportion of GH-secreting pituitary adenomas.
  • Due to the monoallelic origin of Gsalpha in normal pituitary gsp mutations occur on a maternal allele in order to have a phenotypic effect in both sporadic GH-secreting adenomas and those associated with the McCune-Albright syndrome.
  • Therefore, genetic and epigenetic alterations of the GNAS gene, with subsequent dysregulation of the cAMP pathway, appear, to date, the only molecular hallmark of most GH-secreting adenomas.
  • [MeSH-minor] Animals. Cyclic AMP-Dependent Protein Kinases / metabolism. Fibrous Dysplasia, Polyostotic / genetics. Genomic Imprinting. Growth Hormone-Secreting Pituitary Adenoma / genetics. Humans. Mice. Pituitary Gland / pathology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20398730.001).
  • [ISSN] 1872-8057
  • [Journal-full-title] Molecular and cellular endocrinology
  • [ISO-abbreviation] Mol. Cell. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] EC 2.7.11.11 / Cyclic AMP-Dependent Protein Kinases; EC 3.6.1.- / GNAS protein, human; EC 3.6.1.- / Gnas protein, mouse; EC 3.6.5.1 / GTP-Binding Protein alpha Subunits, Gs
  •  go-up   go-down


3. Jaffar R, Mohanty SK, Khan A, Fischer AH: Hemosiderin laden macrophages and hemosiderin within follicular cells distinguish benign follicular lesions from follicular neoplasms. Cytojournal; 2009;6:3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hemosiderin laden macrophages and hemosiderin within follicular cells distinguish benign follicular lesions from follicular neoplasms.
  • BACKGROUND: Published criteria to distinguish benign colloid nodules from follicular neoplasms emphasize only three interdependent features: size of follicles, amount of colloid, and cellularity.
  • The cohort consisted of 165 patients with fine needle aspiration (FNA) and histologic follow-up of either goiter (101), follicular adenoma (47), or follicular carcinoma (17).
  • All four follicular neoplasms with hemosiderin in macrophages were adenomas.
  • Three of these four had equivocal features of a benign colloid nodule histologically.
  • CONCLUSIONS: If papillary thyroid carcinoma and Hürthle cell neoplasm are ruled out, our findings indicate that the presence of hemosiderin virtually excludes a clinically significant follicular neoplasm.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cytojournal. 2008;5:6 [18394201.001]
  • [Cites] Diagn Cytopathol. 2007 Aug;35(8):525-8 [17636488.001]
  • [Cites] Cytopathology. 2007 Apr;18(2):105-11 [17397495.001]
  • [Cites] Cytopathology. 1999 Jun;10(3):171-9 [10390065.001]
  • [Cites] J Ultrasound Med. 2003 Oct;22(10):1083-90 [14606565.001]
  • [Cites] Acta Cytol. 1992 Mar-Apr;36(2):142-6 [1542996.001]
  • [Cites] Acta Cytol. 1989 Jan-Feb;33(1):53-60 [2916371.001]
  • [Cites] Cancer. 1986 Mar 15;57(6):1164-70 [3943039.001]
  • [Cites] Acta Cytol. 1990 May-Jun;34(3):345-51 [2343690.001]
  • [Cites] Mayo Clin Proc. 1994 Jan;69(1):44-9 [8271850.001]
  • (PMID = 19495407.001).
  • [ISSN] 1742-6413
  • [Journal-full-title] CytoJournal
  • [ISO-abbreviation] Cytojournal
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2678825
  • [Keywords] NOTNLM ; Benign colloid nodule / follicular cells / hemosiderin laden macrophages / hemosiderin within follicular neoplasms / macrophages
  •  go-up   go-down


Advertisement
4. Nanashima A, Takeshita H, Tobinaga S, Araki M, Sumida Y, Kunizaki M, Tanaka K, Abo T, Hidaka S, Sawai T, Yasutake T, Nagayasu T: Measurement of serum marker for bone metastasis (1-CTP) in hepatobiliary and pancreas malignancies. Hepatogastroenterology; 2010 Jul-Aug;57(101):694-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODOLOGY: The subjects were 75 patients who underwent surgical resections including 27 patients with liver carcinomas, 15 with extra-hepatic biliary carcinomas, 14 pancreatic carcinomas and 19 benign diseases.
  • RESULTS: 1CTP level tended to be higher in the malignant diseases than in benign diseases but this difference was not significant (p = 0.065).
  • Compared to benign adenoma, 1CTP level in the malignant diseases was significantly higher (p = 0.049).
  • 1CTP level tended to be higher in patients with cholangitis compared to those with no inflammation or benign tumors (p = 0.065).
  • 1CTP was not correlated with any tumor markers.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cholangitis / blood. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21033212.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Collagen Type I; 0 / Peptides; 0 / collagen type I trimeric cross-linked peptide
  •  go-up   go-down


5. Mendoza PL, Ongkeko EE, Santiago JF: Silent parathyroid adenoma mistakenly interpreted on FDG-PET as thyroid cancer metastasis in a patient with elevated thyroglobulin and negative I-131 whole body scan and removed by radioguided minimally invasive surgery. Clin Nucl Med; 2008 Jan;33(1):23-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Silent parathyroid adenoma mistakenly interpreted on FDG-PET as thyroid cancer metastasis in a patient with elevated thyroglobulin and negative I-131 whole body scan and removed by radioguided minimally invasive surgery.
  • Histopathology, however, revealed a parathyroid adenoma.

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18097251.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 9010-34-8 / Thyroglobulin; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


6. Gilat H, Cohen M, Feinmesser R, Benzion J, Shvero J, Segal K, Ulanovsky D, Shpitzer T: Minimally invasive procedure for resection of a parathyroid adenoma: the role of preoperative high-resolution ultrasonography. J Clin Ultrasound; 2005 Jul-Aug;33(6):283-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimally invasive procedure for resection of a parathyroid adenoma: the role of preoperative high-resolution ultrasonography.
  • PURPOSE: Solitary adenoma of the parathyroid is the major cause of primary hyperparathyroidism.
  • Many centers advocate a minimally invasive surgical approach, wherein the surgeon explores only a localized area of the neck according to the preoperative imaging evaluation, and the adenoma is resected without histological sampling from the other parathyroid glands.
  • The aim of this study was to evaluate the ability of high-resolution ultrasonography (US) to localize adenomas preoperatively and thereby aid in patient selection for minimal procedures.
  • METHODS: We reviewed the medical records of 77 consecutive patients who underwent resection of a parathyroid adenoma following ultrasonographic imaging between 2001 and 2002, and we assessed the accuracy of the preoperative localization of the adenomas as well as the efficacy of the minimally invasive procedure.
  • RESULTS: US correctly localized the adenoma to a specific quadrant of the neck in 87% of the cases and to a specific side of the neck in 94%.
  • Its sensitivity was not reduced by the presence of nodular disease of the thyroid gland.
  • CONCLUSIONS: US performed by a skilled operator is a reliable tool for adenoma localization prior to minimally invasive parathyroidectomy.
  • If there is a high clinical suspicion of adenoma in the presence of negative imaging studies, bilateral neck exploration should be performed.
  • [MeSH-major] Adenoma / surgery. Minimally Invasive Surgical Procedures / methods. Parathyroid Glands / ultrasonography. Parathyroid Neoplasms / surgery. Preoperative Care / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16134156.001).
  • [ISSN] 0091-2751
  • [Journal-full-title] Journal of clinical ultrasound : JCU
  • [ISO-abbreviation] J Clin Ultrasound
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Takashima K, Ito Y, Gonzalez FJ, Nakajima T: Different mechanisms of DEHP-induced hepatocellular adenoma tumorigenesis in wild-type and Ppar alpha-null mice. J Occup Health; 2008;50(2):169-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Different mechanisms of DEHP-induced hepatocellular adenoma tumorigenesis in wild-type and Ppar alpha-null mice.
  • A recent study revealed that long-term exposure to relatively low-dose DEHP (0.05%) caused liver tumors including hepatocellular carcinomas, hepatocellular adenomas, and chologiocellular carcinomas at a higher incidence in Ppar alpha-null mice (25.8%) than in wild-type mice (10.0%).
  • Using tissues with hepatocellular adenoma, microarray (Affymetrix MOE430A) as well as, in part, real-time quantitative PCR analysis was conducted to elucidate the mechanisms of the adenoma formation resulting from DEHP exposure in both genotyped mice.
  • The microarray profiles showed that the up- or down-regulated genes were quite different between hepatocellular adenoma tissues of wild-type and Ppar alpha-null mice exposed to DEHP.
  • The gene expressions of apoptotic peptidase activating factor 1 (Apaf1) and DNA-damage-inducible 45 alpha (Gadd45a) were increased in the hepatocellular adenoma tissues of wild-type mice exposed to DEHP, whereas they were unchanged in corresponding tissues of Ppar alpha-null mice.
  • On the other hand, the expressions of cyclin B2 and myeloid cell leukemia sequence 1 were increased only in the hepatocellular adenoma tissues of Ppar alpha-null mice.
  • Taken together, DEHP may induce hepatocellular adenomas, in part, via suppression of G2/M arrest regulated by Gadd45a and caspase 3-dependent apoptosis in Ppar alpha-null mice, but these genes may not be involved in tumorigenesis in the wild-type mice.
  • In contrast, the expression level of Met was notably increased in the liver adenoma tissue of wild-type mice, which may suggest the involvement of Met in DEHP-induced tumorigenesis in wild-type mice.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BIS(2-ETHYLHEXYL) PHTHALATE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18403868.001).
  • [ISSN] 1348-9585
  • [Journal-full-title] Journal of occupational health
  • [ISO-abbreviation] J Occup Health
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Apaf1 protein, mouse; 0 / Apoptotic Protease-Activating Factor 1; 0 / Cell Cycle Proteins; 0 / Gadd45a protein, mouse; 0 / Nuclear Proteins; 0 / PPAR alpha; 0 / Plasticizers; 0 / RNA, Messenger; C42K0PH13C / Diethylhexyl Phthalate; EC 3.4.22.- / Caspase 3
  •  go-up   go-down


8. Folker MB, Bernstein IT, Holck S: [Serrated, hyperplastic and hyperplasia-like colorectal polyps]. Ugeskr Laeger; 2006 Nov 13;168(46):4005-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The colorectal hyperplastic polyp has generally been considered a finding of no clinical significance.
  • The term "advanced serrated polyp" has been coined for such cases, which comprise mixed hyperplastic/adenomatous tissue, serrated adenoma, and sessile serrated polyp, in contrast to the traditional hyperplastic polyp.
  • Since epithelial dysplasia is an integrated component of mixed hyperplastic/adenomatous polyp and of the serrated adenoma, such a diagnosis would dictate control colonoscopy comparable to the guidelines for subjects with conventional adenomas.
  • The cytology of the sessile serrated polyp is, however, closer to that of the traditional hyperplastic polyp, whereas the architecture mimics that of the serrated adenoma.
  • [MeSH-major] Adenoma / pathology. Colonic Polyps / pathology. Colorectal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17125655.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Denmark
  • [Number-of-references] 40
  •  go-up   go-down


9. Stern MC, Siegmund KD, Corral R, Haile RW: XRCC1 and XRCC3 polymorphisms and their role as effect modifiers of unsaturated fatty acids and antioxidant intake on colorectal adenomas risk. Cancer Epidemiol Biomarkers Prev; 2005 Mar;14(3):609-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] XRCC1 and XRCC3 polymorphisms and their role as effect modifiers of unsaturated fatty acids and antioxidant intake on colorectal adenomas risk.
  • Using a large sigmoidoscopy-based case-control study (753 cases and 799 controls) in Los Angeles County, we investigated possible associations between single-nucleotide polymorphisms in the XRCC1 (codons 194 Arg/Trp and codon 399 Arg/Gln) and XRCC3 (codon 241 Thr/Met) genes and colorectal adenoma risk and their possible role as modifiers of the effect of monounsaturated fatty acid, the ratio of omega-6/omega-3 polyunsaturated fatty acids, and antioxidant intake.
  • Subjects with the XRCC1 Gln/Gln genotype were inversely associated with adenoma risk (odds ratio, 0.6; 95% confidence interval, 0.4-0.9; P = 0.01) when compared with subjects with Arg/Arg and Arg/Gln genotypes combined.
  • High monounsaturated fatty acid intake was associated with adenoma risk only among subjects with the XRCC1 codon 194 Arg/Arg and codon 399 Gln/Gln combined genotypes (P for interaction = 0.018).
  • High omega-6/omega-3 polyunsaturated fatty acid ratios were associated with adenoma risk among subjects with the XRCC1 codon 194 Arg/Arg and codon 399 Gln/Gln or the codon 194 Arg/Trp or Trp/Trp and codon 399 Arg/Arg or Arg/Gln combined genotypes (P for interaction = 0.026).
  • Our data suggest that the XRCC1 codon 194 and codon 399 single nucleotide polymorphisms may modify the effect of unsaturated fatty acid and antioxidant intake and that this XRCC1 effect modification may explain, in part, previously reported inconsistencies on the role of unsaturated fatty acids and adenoma risk.
  • [MeSH-major] Adenoma / etiology. Adenoma / genetics. Antioxidants / pharmacology. Colorectal Neoplasms / etiology. Colorectal Neoplasms / genetics. DNA-Binding Proteins / genetics. Dietary Fats, Unsaturated / pharmacology. Polymorphism, Genetic

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15767338.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1R01CA096830
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 0 / DNA-Binding Proteins; 0 / Dietary Fats, Unsaturated; 0 / X-ray repair cross complementing protein 1; 0 / X-ray repair cross complementing protein 3
  •  go-up   go-down


10. Niedźwiecki S, Stepień T, Kuzdak K, Stepień H, Krupiński R, Seehofer D, Rayes N, Ulrich F: Serum levels of interleukin-1 receptor antagonist (IL-1ra) in thyroid cancer patients. Langenbecks Arch Surg; 2008 May;393(3):275-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: We measured preoperative IL-1ra serum levels of 52 consecutive patients with thyroid cancer, 15 with benign adenoma and 27 healthy volunteers.
  • Except for the stage IV disease in ATC, there was no correlation between IL-1ra levels and International Union Against Cancer staging.
  • [MeSH-major] Biomarkers, Tumor / blood. Interleukin 1 Receptor Antagonist Protein / blood. Thyroid Neoplasms / blood
  • [MeSH-minor] Adenocarcinoma, Follicular / blood. Adenocarcinoma, Follicular / surgery. Adenocarcinoma, Papillary / blood. Adenocarcinoma, Papillary / surgery. Adenoma / blood. Adenoma / surgery. Adult. Aged. Carcinoma / blood. Carcinoma / surgery. Carcinoma, Medullary / blood. Carcinoma, Medullary / surgery. Female. Humans. Male. Middle Aged. Reference Values. Sex Factors. Young Adult

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Langenbecks Arch Surg. 2009 Mar;394(2):401-2; author reply 403 [18825404.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):11008-13 [8855299.001]
  • [Cites] Lancet. 1987 Nov 28;2(8570):1240-2 [2890857.001]
  • [Cites] Breast Cancer Res Treat. 2006 Mar;96(2):197-202 [16319982.001]
  • [Cites] Ann Oncol. 2003 Oct;14(10):1501-4 [14504049.001]
  • [Cites] Am J Med. 1990 Nov;89(5):621-9 [2239982.001]
  • [Cites] J Immunol. 1991 Dec 15;147(12):4218-23 [1836481.001]
  • [Cites] Am J Pathol. 1993 Sep;143(3):794-803 [8362978.001]
  • [Cites] Br J Obstet Gynaecol. 1997 Dec;104(12):1407-8 [9422021.001]
  • [Cites] J Am Coll Surg. 1994 Feb;178(2):132-8 [8173722.001]
  • [Cites] Scand J Gastroenterol. 1999 Nov;34(11):1139-43 [10582766.001]
  • [Cites] Int J Cancer. 1997 Jun 11;71(6):1066-76 [9185713.001]
  • [Cites] Am J Pathol. 1992 Feb;140(2):269-75 [1531398.001]
  • [Cites] Cancer Lett. 1999 Aug 3;142(2):179-84 [10463774.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2007 Apr;292(4):R1667-74 [17138728.001]
  • [Cites] J Int Med Res. 2007 May-Jun;35(3):395-405 [17593869.001]
  • [Cites] J Biol Chem. 1991 Jun 5;266(16):10331-6 [1828071.001]
  • [Cites] Blood. 1992 May 1;79(9):2196-200 [1533321.001]
  • [Cites] Blood. 1991 Apr 15;77(8):1627-52 [1826616.001]
  • [Cites] Blood. 1994 Apr 1;83(7):1738-43 [7908231.001]
  • [Cites] Arthritis Rheum. 1995 Aug;38(8):1055-9 [7639800.001]
  • [Cites] J Exp Med. 1999 Jun 21;189(12):1863-74 [10377182.001]
  • [Cites] Annu Rev Immunol. 1998;16:27-55 [9597123.001]
  • [Cites] J Clin Invest. 1997 Jun 15;99(12):2930-40 [9185517.001]
  • [Cites] Eur J Cardiothorac Surg. 2007 Apr;31(4):719-24 [17317198.001]
  • [Cites] Gynecol Oncol. 1991 Aug;42(2):161-4 [1832651.001]
  • [Cites] Scand J Immunol. 1998 Mar;47(3):195-8 [9519856.001]
  • [Cites] J Soc Gynecol Investig. 2002 Nov-Dec;9(6):386-90 [12445604.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2339-45 [15800325.001]
  • [Cites] J Immunol. 1993 May 1;150(9):4008-18 [8473746.001]
  • [Cites] Clin Infect Dis. 2002 Jan 15;34(2):204-9 [11740709.001]
  • [Cites] Eur Cytokine Netw. 1994 Nov-Dec;5(6):517-31 [7727685.001]
  • [Cites] Br J Cancer. 2005 Aug 22;93(4):493-7 [16106254.001]
  • [Cites] Prog Growth Factor Res. 1990;2(4):193-205 [2151936.001]
  • [Cites] Blood. 1996 Apr 15;87(8):3282-8 [8605344.001]
  • [Cites] Clin Exp Immunol. 1995 Feb;99(2):303-10 [7851026.001]
  • [Cites] Gastric Cancer. 2006;9(4):284-90 [17235630.001]
  • [Cites] Int J Oncol. 1999 Dec;15(6):1251-4 [10568836.001]
  • [Cites] Lancet. 1992 Oct 17;340(8825):968 [1357359.001]
  • [Cites] Pharmacol Res. 2007 Feb;55(2):131-8 [17174563.001]
  • [Cites] Nan Fang Yi Ke Da Xue Xue Bao. 2007 Mar;27(3):387-9 [17426001.001]
  • [Cites] Arthritis Rheum. 1994 Dec;37(12):1744-51 [7986220.001]
  • (PMID = 18064485.001).
  • [ISSN] 1435-2451
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / IL1RN protein, human; 0 / Interleukin 1 Receptor Antagonist Protein
  •  go-up   go-down


11. Oikarinen SI, Pajari AM, Salminen I, Heinonen SM, Adlercreutz H, Mutanen M: Effects of a flaxseed mixture and plant oils rich in alpha-linolenic acid on the adenoma formation in multiple intestinal neoplasia (Min) mice. Br J Nutr; 2005 Oct;94(4):510-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of a flaxseed mixture and plant oils rich in alpha-linolenic acid on the adenoma formation in multiple intestinal neoplasia (Min) mice.
  • To study the effects of a flaxseed mixture on adenoma formation in multiple intestinal neoplasia mice, the mice were fed a diet containing 2.7 % flaxseed, 4.5 % fibre and 3.7 % ALA.
  • The median number of adenomas in the small intestine was fifty-four for the control group, and thirty-seven (P=0.023) and forty-two (P=0.095) for flaxseed and oil groups, respectively.
  • Compared with controls (1.2 mm), the adenoma size was smaller in the flaxseed (0.9 mm; P=0.002) and oil (1.0 mm; P=0.012) groups.
  • Both diets changed the proportions of n-3 and n-6 fatty acids in the colonic mucosa.
  • Membrane beta-catenin and protein kinase C (PKC)-zeta levels were reduced in the adenoma v. mucosa (P<0.05), and an inverse association was found between the membrane PKC-zeta in the mucosa and the adenoma number (r -0.460, P=0.008, n 32).
  • [MeSH-major] Adenoma / prevention & control. Flax. Intestinal Neoplasms / prevention & control. Neoplasms, Multiple Primary / prevention & control. Plant Oils / administration & dosage. alpha-Linolenic Acid / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LINSEED OIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16197574.001).
  • [ISSN] 0007-1145
  • [Journal-full-title] The British journal of nutrition
  • [ISO-abbreviation] Br. J. Nutr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Actins; 0 / Fatty Acids; 0 / Lignans; 0 / Plant Oils; 0 / beta Catenin; 0RBV727H71 / alpha-Linolenic Acid; 8001-26-1 / Linseed Oil; EC 1.14.99.1 / Cyclooxygenase 2; EC 2.7.11.13 / Protein Kinase C
  •  go-up   go-down


12. Xiao P, Xue L, Peng JJ, Feng ST, Liao B, Wen JM: An intrasellar mixed gangliocytoma-adenoma including ependymal component, and review of the literature. BMJ Case Rep; 2009;2009
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An intrasellar mixed gangliocytoma-adenoma including ependymal component, and review of the literature.
  • A rare case of intrasellar mixed gangliocytoma-adenoma including ependymal component, which presented clinically with acromegaly and menstrual disorder, is described here.
  • A histological examination of the resected specimen showed that the tumour was composed of ganglion cells, adenomatous cells and ependymal cells.
  • Most intrasellar gangliocytomas are composed of two components: adenomatous cells and ganglion cells.
  • In this case, in addition to mixed adenomatous and ganglion cells, focal ependymal cells forming small cysts were found.
  • Based on these histopathological findings, it was inferred that stem cells existed in the pituitary gland during embryonic development.
  • The stem cells were able to differentiate into three directions: ganglion cells, adenomatous cells and ependymal cells, and as a result an intrasellar mixed gangliocyto-adenoma including ependymal component developed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2000 Apr;24(4):607-13 [10757410.001]
  • [Cites] Brain Pathol. 2002 Jul;12(3):391-2, 397 [12146807.001]
  • [Cites] Acta Neuropathol. 2002 Oct;104(4):435-40 [12200632.001]
  • [Cites] Arch Pathol Lab Med. 2005 Mar;129(3):415-6 [15737044.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4240-5 [8633048.001]
  • [Cites] Minim Invasive Neurosurg. 1997 Sep;40(3):107-9 [9359090.001]
  • [Cites] Neurosurgery. 1997 Mar;40(3):611-4; discussion 614-5 [9055303.001]
  • [Cites] Brain Tumor Pathol. 2002;19(2):63-7 [12622135.001]
  • [Cites] J Endocrinol Invest. 2005 Feb;28(2):162-5 [15887863.001]
  • [Cites] Acta Neuropathol. 2006 Jul;112(1):21-8 [16699777.001]
  • [Cites] Hum Pathol. 1989 Dec;20(12):1198-203 [2591950.001]
  • [Cites] Ultrastruct Pathol. 1994 Nov-Dec;18(6):565-74 [7855931.001]
  • [Cites] Virchows Arch. 1994;425(1):93-9 [7921420.001]
  • [Cites] Neurosurgery. 1993 Nov;33(5):920-4; discussion 924-5 [8264895.001]
  • (PMID = 21686419.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3029532
  •  go-up   go-down


13. Pohl J, Lotterer E, Balzer C, Sackmann M, Schmidt KD, Gossner L, Schaab C, Frieling T, Medve M, Mayer G, Nguyen-Tat M, Ell C: Computed virtual chromoendoscopy versus standard colonoscopy with targeted indigocarmine chromoscopy: a randomised multicentre trial. Gut; 2009 Jan;58(1):73-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Computed virtual chromoendoscopy with the Fujinon intelligent colour enhancement (FICE) system is a new dyeless imaging technique that might allow higher rates of adenoma detection.
  • In total, 236 adenomas (mean of 0.64 per case) were detected in the FICE group and 271 adenomas (mean of 0.68 per case) in the control group (p = 0.92).
  • There was no statistically significant difference in the percentage of patients with >or=1 adenoma between the control group (35.4%) and the FICE group (35.6%) (p = 1.0).
  • For the differential diagnosis of adenomas and non-neoplastic polyps, the sensitivity of FICE (92.7%) was comparable with that of indigocarmine (90.4%) (p = 0.44).
  • CONCLUSIONS: At colonoscopy, adenoma detection rates are not improved by virtual chromoendoscopy with the FICE system compared with white light endoscopy with targeted indigocarmine spraying.
  • [MeSH-major] Adenoma / diagnosis. Colonoscopy / methods. Colorectal Neoplasms / diagnosis


14. Augoff K, Rabczynski J, Tabola R, Czapla L, Ratajczak K, Grabowski K: Immunohistochemical study of decorin expression in polyps and carcinomas of the colon. Med Sci Monit; 2008 Oct;14(10):CR530-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Recent studies showed that a small leucine-rich proteoglycan, decorin, may suppress tumor progression as a natural anticancer agent negatively controlling cellular growth.
  • It was hypothesized that physiological expression of decorin may be associated with cellular senescence of the colorectal mucosa and that its down-regulation, promoting an increase in cellular proliferation, could participate in the progression of adenoma to adenocarcinoma.
  • MATERIAL/METHODS: Tissue samples were obtained from 41 patients with different types of colonic polyps (6 hyperplastic adenomas, 34 neoplastic adenomas, and 1 adenomatous polyp with focal carcinoma) and 12 patients with colon cancer.
  • RESULTS: Normal and hyperplastic tissues and the majority of tubular adenomas showed strong expression of decorin in the stroma.
  • Adenomas with a villous component showed moderate and very low decorin immunoreactivity.
  • The decrease in decorin reactivity in tubulo-villous adenomas was significant as compared with other polyps and controls.

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18830193.001).
  • [ISSN] 1643-3750
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / DCN protein, human; 0 / Decorin; 0 / Extracellular Matrix Proteins; 0 / Proteoglycans
  •  go-up   go-down


15. Arber N, Levin B: Chemoprevention of colorectal neoplasia: the potential for personalized medicine. Gastroenterology; 2008 Apr;134(4):1224-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoprevention of colorectal neoplasia: the potential for personalized medicine.
  • The poor survival rate of advanced CRC has prompted the emphasis on prevention of this disease.
  • CRC screening and removal of adenomas is an effective intervention, and is the cornerstone of prevention.
  • Chemoprevention involves the long-term use of a variety of oral agents that can delay, prevent or even reverse the development of adenomas in the large bowel, thus interfering with the multi-step progessing from adenoma to carcinoma.
  • This effect is of particular importance to individuals with a hereditary prediposition to colorectal neoplasia and to those who are especially susceptile to the environmental causes of CRC.
  • Sulindac and celecoxib are effective in promoting poly regression in high risk individuals with Familial Adenomatous Polyposis (FAP).
  • In the more common sporadic setting the APROVe (refecoxib), APC and PreSAP (Celecoxib) trials have shown a significant reduction in adenoma recurrence but important concerns exist regarding cardiovascular toxicity associated with selective COX-2 inhibitors.
  • These landmark studies are very important, as they provide a proof of concept that we can prevent high risk adenomas that can lead to CRC development.


16. Kazakov DV, Schaller J, Vanecek T, Kacerovska D, Michal M: Brooke-Spiegler syndrome: report of a case with a novel mutation in the CYLD gene and different types of somatic mutations in benign and malignant tumors. J Cutan Pathol; 2010 Aug;37(8):886-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brooke-Spiegler syndrome: report of a case with a novel mutation in the CYLD gene and different types of somatic mutations in benign and malignant tumors.
  • Whereas one of the two BCCs manifested a conventional morphology, the second neoplasm additionally showed foci with high grade cytological features characterized by marked pleomorphism and numerous mitotic figures.
  • [MeSH-major] Adenoma / genetics. Carcinoma, Adenoid Cystic / genetics. Carcinoma, Basal Cell / genetics. Carcinoma, Skin Appendage / genetics. Facial Neoplasms / genetics. Skin Neoplasms / genetics. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Brooke-Spiegler syndrome.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20132422.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / CYLD protein, human; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


17. van der Windt DJ, Kok NF, Hussain SM, Zondervan PE, Alwayn IP, de Man RA, IJzermans JN: Case-orientated approach to the management of hepatocellular adenoma. Br J Surg; 2006 Dec;93(12):1495-502
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case-orientated approach to the management of hepatocellular adenoma.
  • BACKGROUND: Treatment of suspected hepatocellular adenoma (HA) remains controversial.
  • CONCLUSION: Observation of adenomas smaller than 5 cm is justified because of improved radiological reliability.
  • [MeSH-major] Adenoma, Liver Cell / diagnosis. Liver Neoplasms / diagnosis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17051603.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contraceptives, Oral
  •  go-up   go-down


18. Giannone N, Lo Muzio L, Politi M: Extracapsular lumpectomy and SMAS flap for benign parotid tumours: an early outcome in a small number of cases on Frey's syndrome and facial nerve dysfunction. J Craniomaxillofac Surg; 2008 Jun;36(4):239-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extracapsular lumpectomy and SMAS flap for benign parotid tumours: an early outcome in a small number of cases on Frey's syndrome and facial nerve dysfunction.
  • Parotidectomy is the most common approach for benign salivary neoplasms.
  • The aim of the present study was to retrospectively analyse no. 34 extracapsular lumpectomies (ELs) performed with superficial musculoaponeurotic system (SMAS) flaps on 32 patients for benign parotid tumours.
  • None of the patients affected by pleomorphic adenoma or Warthin's tumour had a complete facial palsy.
  • [MeSH-major] Adenolymphoma / surgery. Adenoma, Pleomorphic / surgery. Oral Surgical Procedures / adverse effects. Parotid Neoplasms / surgery. Surgical Flaps

  • Genetic Alliance. consumer health - Frey's Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18313936.001).
  • [ISSN] 1010-5182
  • [Journal-full-title] Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery
  • [ISO-abbreviation] J Craniomaxillofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


19. Schroy PC 3rd, Glick JT, Wilson S, Robinson PA, Heeren TC: An effective educational strategy for improving knowledge, risk perception, and risk communication among colorectal adenoma patients. J Clin Gastroenterol; 2008 Jul;42(6):708-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An effective educational strategy for improving knowledge, risk perception, and risk communication among colorectal adenoma patients.
  • BACKGROUND: We have previously shown that most adenoma patients are unaware of the personal and familial implications of their diagnosis.
  • METHODS: Using a quasi-randomized design, adenoma-bearing subjects were assigned to the CBEP +PL (n=99), CBEP (n=96), or SC (n=120) arms.
  • Subjects in the CBEP+PL group were more likely (P<0.05) than those in the SC group to know that adenomas but not hyperplastic polyps were precancerous, that patients with adenomas were at increased risk of future adenomas, and that the siblings and children of adenoma patients may be at increased colorectal cancer risk.
  • Subjects in the CBEP+PL group were also more likely (P<0.05) to know their polyp's histology, perceive themselves and their siblings/children to be at increased risk of colorectal neoplasia, and notify a first-degree relative.
  • CONCLUSIONS: The CBEP+PL intervention is an effective strategy for improving knowledge, risk perception, and risk communication among adenoma patients.
  • [MeSH-major] Adenomatous Polyps / psychology. Colorectal Neoplasms / psychology. Health Knowledge, Attitudes, Practice. Patient Education as Topic / methods

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18574393.001).
  • [ISSN] 1539-2031
  • [Journal-full-title] Journal of clinical gastroenterology
  • [ISO-abbreviation] J. Clin. Gastroenterol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K22-CA90680
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


20. Robertson DJ, Sandler RS, Haile R, Tosteson TD, Greenberg ER, Grau M, Baron JA: Fat, fiber, meat and the risk of colorectal adenomas. Am J Gastroenterol; 2005 Dec;100(12):2789-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fat, fiber, meat and the risk of colorectal adenomas.
  • OBJECTIVE: The aim of this study was to determine the relationship between fat, fiber, and meat intake, and risk of colorectal adenoma recurrence.
  • METHODS: We determined adenoma recurrence and dietary intake for 1,520 participants in two randomized trials: The Antioxidant Polyp Prevention Study and Calcium Polyp Prevention Study.
  • Subjects underwent baseline colonoscopy with removal of all adenomas, and dietary intake was estimated with a validated semiquantitative food frequency questionnaire.
  • Pooled risk ratios for adenoma recurrence were obtained by generalized linear regression, with adjustment for age, sex, clinical center, treatment category, study, and duration of observation.
  • RESULTS: In the total colorectum, fiber intake was weakly and nonsignificantly associated with a risk for all adenomas (RR quartile 4 vs quartile 1=0.85, 95% CI 0.69-1.05) and advanced adenomas (RR=0.88, 95% CI 0.54-1.44).
  • Associations were stronger for adenomas in the proximal colon (RR=0.73, 95% CI 0.56-0.97) and some fiber subtypes (fruit and vegetable, grain).
  • There was no association between fat or total red meat intake and risk of adenoma or advanced adenoma recurrence.
  • However, when considering other meats, risk (quartile 4 vs quartile 1) for advanced adenoma was increased for processed meat (RR=1.75, 95% CI 1.02-2.99) and decreased for chicken (RR=0.61, 95% CI 0.38-0.98).
  • CONCLUSION: The inverse associations between fiber intake and risk of adenoma recurrence we observed are weak, and not statistically significant.
  • [MeSH-major] Adenoma / therapy. Colorectal Neoplasms / therapy. Diet. Dietary Fats / adverse effects. Dietary Fiber / administration & dosage. Neoplasm Recurrence, Local / prevention & control

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Dietary Fats.
  • MedlinePlus Health Information. consumer health - Dietary Fiber.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16393237.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA23108; United States / NCI NIH HHS / CA / CA46927
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dietary Fats
  •  go-up   go-down


21. Mullaney PJ, Becker E, Graham B, Ghazarian D, Riddell RH, Salonen DC: Benign hidradenoma: magnetic resonance and ultrasound features of two cases. Skeletal Radiol; 2007 Dec;36(12):1185-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign hidradenoma: magnetic resonance and ultrasound features of two cases.
  • Tumors of sweat gland origin are rare in the hand but should be considered in the differential diagnosis when certain imaging features are present.
  • The imaging literature of this tumor is reviewed, and its significance is discussed with respect to the current understanding of its malignant potential.
  • [MeSH-major] Adenoma, Sweat Gland / diagnosis. Fingers. Magnetic Resonance Imaging. Sweat Gland Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Dermatol. 1968 Jun;97(6):651-61 [4297448.001]
  • [Cites] AJR Am J Roentgenol. 2002 Oct;179(4):1079-80 [12239078.001]
  • [Cites] Radiat Med. 2004 Nov-Dec;22(6):426-8 [15648460.001]
  • [Cites] J Surg Oncol. 1990 Feb;43(2):131-3 [2154644.001]
  • [Cites] Breast J. 2007 Jan-Feb;13(1):91-3 [17214802.001]
  • [Cites] J Am Podiatr Med Assoc. 1998 Oct;88(10):510-3 [9791957.001]
  • [Cites] Skeletal Radiol. 1999 Feb;28(2):104-6 [10197457.001]
  • [Cites] Clin Radiol. 2004 Dec;59(12 ):1142-4 [15556599.001]
  • [Cites] Am Surg. 1999 Mar;65(3):236-40 [10075300.001]
  • [Cites] J Comput Assist Tomogr. 2000 Mar-Apr;24(2):293-5 [10752896.001]
  • (PMID = 17624528.001).
  • [ISSN] 0364-2348
  • [Journal-full-title] Skeletal radiology
  • [ISO-abbreviation] Skeletal Radiol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


22. Kim S, Keku TO, Martin C, Galanko J, Woosley JT, Schroeder JC, Satia JA, Halabi S, Sandler RS: Circulating levels of inflammatory cytokines and risk of colorectal adenomas. Cancer Res; 2008 Jan 1;68(1):323-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating levels of inflammatory cytokines and risk of colorectal adenomas.
  • The association between obesity and colorectal neoplasia may be mediated by inflammation.
  • Circulating levels of C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) are elevated in the obese.
  • We examined circulating levels of CRP, IL-6, and TNF-alpha in relation to risk factors and the prevalence of colorectal adenomas.
  • Plasma levels of CRP, IL-6, and TNF-alpha were quantified in 873 participants (242 colorectal adenoma cases and 631 controls) in a colonoscopy-based cross-sectional study conducted between 1998 and 2002.
  • Multivariable logistic regression was used to estimate associations between known risk factors for colorectal neoplasia and circulating levels of inflammatory cytokines and associations between inflammatory cytokines and colorectal adenomas.
  • Several known risk factors for colorectal neoplasia were associated with higher levels of inflammatory cytokines, including older age, current smoking, and increasing adiposity.
  • The prevalence of colorectal adenomas was associated with higher concentrations of IL-6 and TNF-alpha and, to a lesser degree, with CRP.
  • For IL-6, adjusted odds ratios (OR) for colorectal adenomas were 1.79 [95% confidence interval (CI), 1.19-2.69] for the second highest plasma level and 1.85 (95% CI, 1.24-2.75) for the highest level compared with the reference level.
  • Our findings indicate that systemic inflammation might be involved in the early development of colorectal neoplasia.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 2003 Apr 9;289(14):1799-804 [12684358.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Jun;15(6):1126-31 [16775170.001]
  • [Cites] J Clin Invest. 2003 Dec;112(12):1796-808 [14679176.001]
  • [Cites] JAMA. 2004 Feb 4;291(5):585-90 [14762037.001]
  • [Cites] Nat Rev Cancer. 2004 Aug;4(8):579-91 [15286738.001]
  • [Cites] Obes Res. 2004 Jul;12(7):1094-103 [15292473.001]
  • [Cites] Annu Rev Med. 2000;51:245-70 [10774463.001]
  • [Cites] Lancet. 2001 Feb 17;357(9255):539-45 [11229684.001]
  • [Cites] Clin Chem. 2001 Mar;47(3):426-30 [11238292.001]
  • [Cites] J Am Coll Cardiol. 2001 Jun 15;37(8):2036-41 [11419884.001]
  • [Cites] Proc Nutr Soc. 2001 Aug;60(3):329-39 [11681807.001]
  • [Cites] Am J Epidemiol. 2001 Dec 15;154(12):1089-99 [11744511.001]
  • [Cites] Nutrition. 2001 Nov-Dec;17(11-12):953-66 [11744348.001]
  • [Cites] Am J Epidemiol. 2002 Jan 15;155(2):176-84 [11790682.001]
  • [Cites] Am J Cardiol. 2002 May 1;89(9):1117-9 [11988205.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2002 Oct 1;22(10):1668-73 [12377747.001]
  • [Cites] J Pathol. 2002 Dec;198(4):428-34 [12434411.001]
  • [Cites] Br J Nutr. 2004 Sep;92(3):347-55 [15469638.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2004 Sep;59(9):M924-9 [15472157.001]
  • [Cites] Proc Natl Acad Sci U S A. 1975 Sep;72(9):3666-70 [1103152.001]
  • [Cites] Am J Epidemiol. 1986 Sep;124(3):453-69 [3740045.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jul;82(7):2182-91 [9215292.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 1997 Oct;17(10):2167-76 [9351386.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4601-6 [9539784.001]
  • [Cites] Circulation. 1999 Aug 24;100(8):793-8 [10458713.001]
  • [Cites] J Biol Chem. 2004 Nov 19;279(47):48487-90 [15337754.001]
  • [Cites] Nutr Rev. 2005 Jan;63(1):22-8 [15730232.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2294-9 [15572589.001]
  • [Cites] Ann Intern Med. 2005 Mar 15;142(6):425-32 [15767620.001]
  • [Cites] Cancer Cell. 2005 Mar;7(3):211-7 [15766659.001]
  • [Cites] J Allergy Clin Immunol. 2005 May;115(5):911-9; quiz 920 [15867843.001]
  • [Cites] J Epidemiol. 2005 Jun;15 Suppl 2:S185-9 [16127232.001]
  • [Cites] Psychosom Med. 2005 Sep-Oct;67(5):679-87 [16204423.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2413-8 [16214925.001]
  • [Cites] Nat Rev Cancer. 2006 Jan;6(1):24-37 [16397525.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2483-7 [16489056.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Apr;15(4):690-5 [16614110.001]
  • [Cites] Mech Ageing Dev. 2003 Apr;124(4):487-93 [12714257.001]
  • (PMID = 18172326.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA044684; United States / NCI NIH HHS / CA / R01 CA044684-17; United States / NCI NIH HHS / CA / R01 CA 44684; United States / NIDDK NIH HHS / DK / P30 DK034987; United States / NCI NIH HHS / CA / CA044684-17; United States / NIDDK NIH HHS / DK / P30 DK034987-23; United States / NIDDK NIH HHS / DK / P30 DK34987
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / Interleukin-6; 0 / Tumor Necrosis Factor-alpha
  • [Other-IDs] NLM/ NIHMS92897; NLM/ PMC2675825
  •  go-up   go-down


23. Kinkor Z, Skálová A, Michal M, Janousek M, Kheck M: [Metastasing and relapsing "low grade" adenosquamous metaplastic breast cancer--is there a really indolent lesion? A description of three cases and review of literature]. Ceska Gynekol; 2005 May;70(3):211-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Partial mastectomy and segmentectomy were performed in three women 46, 72 and 74 years-old resp. for tumor, which size ranged from 20-35 mm in maximum diameter (mean 28 mm).
  • Variably present was characteristic squamous metaplasia of the gland forming either luminal morules or evident squamous pearls.
  • There were recognized metastases by one woman in two ipsilateral axillary lymph nodes mimicking benign breast heterotopia in one of them.
  • In two women with aggressive course the original biopsy was falsely interpreted, once as phyllodes tumor and secondly as benign sclerosing pseudotumor.
  • Low-grade adenosquamous carcinoma, however, has nothing to do with syringomatous adenoma of the nipple, which is a benign tumor of the skin adnexa.
  • Differential diagnosis includes spectrum of non-neoplastic slerosing lesions and above-mentioned phylloid tumor.
  • The rarity of this neoplasm does not exclude deep knowledge.


24. Katori H, Nozawa A, Tsukuda M: Expression of epidermal growth factor receptor, transforming growth factor-alpha and Ki-67 in relationship to malignant transformation of pleomorphic adenoma. Acta Otolaryngol; 2007 Nov;127(11):1207-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of epidermal growth factor receptor, transforming growth factor-alpha and Ki-67 in relationship to malignant transformation of pleomorphic adenoma.
  • The data support the hypothesis that increased epidermal growth factor receptor (EGFR) and transforming growth factor (TGF)-alpha expression is associated with early events in malignant transformation of pleomorphic adenoma (PA).
  • OBJECTIVE: In the present study, we attempted to identify EGFR and TGF-alpha expression and Ki-67 index in carcinoma ex-pleomorphic adenoma (Ca ex-PA) and PA.
  • RESULTS: As regards the association of patients' prognosis with EGFR staining and Ki-67 index, a significant increase was observed in patients who died or had residual disease compared with patients who were alive without disease.
  • [MeSH-major] Adenoma, Pleomorphic / metabolism. Biomarkers, Tumor / biosynthesis. Cell Transformation, Neoplastic. Ki-67 Antigen / genetics. Receptor, Epidermal Growth Factor / biosynthesis. Salivary Gland Neoplasms / metabolism. Transforming Growth Factor alpha / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17851915.001).
  • [ISSN] 0001-6489
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Transforming Growth Factor alpha; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


25. Cetani F, Pardi E, Banti C, Collecchi P, Viacava P, Borsari S, Fanelli G, Naccarato AG, Saponaro F, Berti P, Miccoli P, Pinchera A, Marcocci C: Beta-catenin activation is not involved in sporadic parathyroid carcinomas and adenomas. Endocr Relat Cancer; 2010 Mar;17(1):1-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Beta-catenin activation is not involved in sporadic parathyroid carcinomas and adenomas.
  • The aim of this study was to evaluate whether Wnt/beta-catenin signaling is activated in parathyroid carcinomas and adenomas.
  • We studied 154 parathyroid tumors (18 carcinomas (13 with distant metastases), six atypical adenomas, and 130 adenomas).
  • Immunostaining of beta-catenin was performed in all carcinomas and in 66 adenomas (including three atypical).
  • With the exception of one carcinoma, which had a negative membrane staining, all other samples showed a membrane staining which was similar to that of the normal parathyroid. beta-Catenin expression was heterogeneous with a range of positive cells between 5 and 80%, independently of tumor type.
  • Our results suggest that the Wnt/beta-catenin signaling pathway is not involved in the development of parathyroid carcinomas and adenomas.
  • [MeSH-major] Adenoma / physiopathology. Carcinoma / physiopathology. Neoplasm Proteins / physiology. Parathyroid Neoplasms / physiopathology. Signal Transduction / physiology. Wnt Proteins / physiology. beta Catenin / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19755524.001).
  • [ISSN] 1479-6821
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CTNNB1 protein, human; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 0 / Wnt Proteins; 0 / beta Catenin
  •  go-up   go-down


26. Sharon E, Kelly RJ, Szabo E: Sustained response of carcinoma ex pleomorphic adenoma treated with trastuzumab and capecitabine. Head Neck Oncol; 2010;2:12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sustained response of carcinoma ex pleomorphic adenoma treated with trastuzumab and capecitabine.
  • BACKGROUND: Carcinoma ex pleomorphic adenoma is a rare histologic subtype of salivary gland cancer with an overall poor prognosis.
  • We report here a case of a 58-year old man with metastatic carcinoma ex pleomorphic adenoma who achieved a sustained long term response to combination therapy with trastuzumab and capecitabine.
  • CASE PRESENTATION: A 58 year old man presented with T1N2bM0 carcinoma ex pleomorphic adenoma and underwent surgery followed by adjuvant radiation therapy.
  • Since the original tumor was strongly HER2/neu positive by immunohistochemistry, the patient was treated with trastuzumab, capecitabine, and zoledronic acid.
  • He experienced total resolution of symptoms and repeat FDG-PET scan after three cycles revealed interval disease resolution.
  • Continued treatment has resulted in maintenance of disease control for over 2 years.
  • CONCLUSION: This case illustrates the successful long term treatment of carcinoma ex pleomorphic adenoma with targeted therapy with trastuzumab in combination with chemotherapy.
  • In the absence of definitive clinical trials which are unlikely to be performed due to the rarity of this tumor, case reports such as this one suggest potential utility for trastuzumab in combination with chemotherapy in the treatment of HER2/neu-overexpressing carcinoma ex pleomorphic adenoma.
  • [MeSH-major] Adenoma, Pleomorphic / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Salivary Gland Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3246-50 [17577021.001]
  • [Cites] J Clin Oncol. 2007 Sep 1;25(25):3978-84 [17761983.001]
  • [Cites] Head Neck. 2008 May;30(5):680-3 [17972317.001]
  • [Cites] Semin Oncol. 2008 Jun;35(3):309-19 [18544445.001]
  • [Cites] J Laryngol Otol. 2009 Feb;123(2):250-2 [18405406.001]
  • [Cites] Laryngoscope. 1992 Aug;102(8):923-7 [1353853.001]
  • [Cites] Hum Pathol. 2001 Jun;32(6):596-604 [11431714.001]
  • [Cites] Head Neck. 2001 Sep;23(9):705-12 [11505478.001]
  • [Cites] Oral Oncol. 2002 Oct;38(7):706-13 [12167424.001]
  • [Cites] Oral Oncol. 2003 Oct;39(7):724-7 [12907212.001]
  • [Cites] J Clin Oncol. 2006 Jun 10;24(17):2673-8 [16763282.001]
  • (PMID = 20504363.001).
  • [ISSN] 1758-3284
  • [Journal-full-title] Head & neck oncology
  • [ISO-abbreviation] Head Neck Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2889991
  •  go-up   go-down


27. Triggiani V, Guastamacchia E, Lolli I, Troccoli G, Resta F, Sabbà C, Ruggieri N, Tafaro E: Association of a wide invasive malignant thymoma with myastenia gravis and primary hyperparathyroidism due to parathyroid adenoma: case report and review of the literature. Immunopharmacol Immunotoxicol; 2006;28(2):377-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of a wide invasive malignant thymoma with myastenia gravis and primary hyperparathyroidism due to parathyroid adenoma: case report and review of the literature.
  • In these cases the hyperparathyroidism was due to the presence of an adenoma or hyperplasic parathyroid tissue either in the cervical region or in an ectopic intrathymic location.(12345) In other cases the syndrome of hypercalcemia was due to the secretion of parathyroid-related protein (PTHRP) (6) or parathyroid hormone (PTH) (7) by the thymoma itself.
  • We report the first case, at the best of our knowledge, of a wide invasive malignant thymoma (type B3), associated with myasthenia gravis and hyperparathyroidism caused by parathyroid adenoma.
  • [MeSH-major] Adenoma / pathology. Hyperparathyroidism, Primary / pathology. Myasthenia Gravis / pathology. Parathyroid Neoplasms / pathology. Thymus Neoplasms / pathology


28. Wiseman SM, Melck A, Masoudi H, Ghaidi F, Goldstein L, Gown A, Jones SJ, Griffith OL: Molecular phenotyping of thyroid tumors identifies a marker panel for differentiated thyroid cancer diagnosis. Ann Surg Oncol; 2008 Oct;15(10):2811-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The objective of this work was to evaluate the molecular phenotype of differentiated thyroid cancer (DTC) and benign thyroid lesions to identify molecular markers that allow for accurate thyroid cancer diagnosis.
  • METHODS: Tissue microarrays consisting of 100 benign and 105 malignant thyroid lesions, plus 24 lymph node samples, were stained for a panel of 57 molecular markers.
  • Significant associations between marker staining and tumor pathology (DTC versus benign) were determined using contingency table and Mann-Whitney U (MU) tests.
  • Of these, in DTC compared with benign thyroid tumors, 8 markers were downregulated and 27 upregulated.
  • Using the entire molecular marker panel, a Random Forests algorithm was able to classify tumors as DTC or benign with an estimated sensitivity of 87.9%, specificity of 94.0%, and an accuracy of 91.0%.
  • CONCLUSION: Evaluation of the DTC and benign thyroid tumor molecular phenotype has allowed for identification of a marker panel, composed of both established and novel markers, useful for thyroid cancer diagnosis.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma, Follicular / diagnosis. Adenocarcinoma, Follicular / metabolism. Adenoma, Oxyphilic / diagnosis. Adenoma, Oxyphilic / metabolism. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / metabolism. Cell Differentiation. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Phenotype. Prognosis. Tissue Array Analysis

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18612701.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


29. Qian ZR, Asa SL, Siomi H, Siomi MC, Yoshimoto K, Yamada S, Wang EL, Rahman MM, Inoue H, Itakura M, Kudo E, Sano T: Overexpression of HMGA2 relates to reduction of the let-7 and its relationship to clinicopathological features in pituitary adenomas. Mod Pathol; 2009 Mar;22(3):431-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of HMGA2 relates to reduction of the let-7 and its relationship to clinicopathological features in pituitary adenomas.
  • High-mobility group A2 is highly expressed during embryogenesis and in various benign and malignant tumors.
  • The development of pituitary adenomas in high-mobility group A2 transgenic mice showed that high-mobility group A2 may be involved in pituitary tumorigenesis.
  • However, no studies have investigated the clinical significance of high-mobility group A2 and its relationship to the let-7 miRNA family in human pituitary adenomas.
  • Using immunohistochemistry, we analyzed high-mobility group A2 expression with respect to various clinicopathologic factors in 98 pituitary adenomas.
  • Overexpression of high-mobility group A2 was observed in 39% (38/98) of pituitary adenomas compared with normal adenohypophysial tissue and was frequently found in adenomas including prolactin (PRL), adrenocorticotrophic hormone, or follicle-stimulating hormone/luteinizing hormone and in null cell adenomas, but relatively rare in growth hormone (GH) and mixed GH/PRL adenomas.
  • High-mobility group A2 expression was significantly associated with tumor invasion (P<0.05) and was significantly higher in grade IV than in grades I, II, and III adenomas (P<0.05).
  • Real-time quantitative RT-PCR analysis was carried out to evaluate the expression of let-7 in 55 pituitary adenomas.
  • Subsequently, decreased expression of let-7 was confirmed in 23 of 55 (42%) adenomas and was correlated with high-grade tumors (P<0.05).
  • [MeSH-major] Adenoma / genetics. HMGA2 Protein / biosynthesis. MicroRNAs / biosynthesis. Pituitary Neoplasms / genetics
  • [MeSH-minor] Biomarkers, Tumor / genetics. Disease Progression. Female. Gene Expression. Humans. Immunohistochemistry. Male. Reverse Transcriptase Polymerase Chain Reaction. Up-Regulation

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19136928.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HMGA2 Protein; 0 / MicroRNAs; 0 / mirnlet7 microRNA, human
  •  go-up   go-down


30. Shindo ML, Rosenthal JM: Minimal access parathyroidectomy using the focused lateral approach: technique, indication, and results. Arch Otolaryngol Head Neck Surg; 2007 Dec;133(12):1227-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MAIN OUTCOME MEASURES: The FLA was used when preoperative sestamibi single-photon emission computed tomography or ultrasonography showed an adenoma located superiorly, posteriorly, or retroesophageally.
  • Intraoperative rapid parathyroid hormone assay was used to confirm a single adenoma in all cases.
  • The FLA improves the mean excision time for excision of posteriorly located parathyroid adenomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18086964.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Lawrance AK, Deng L, Rozen R: Methylenetetrahydrofolate reductase deficiency and low dietary folate reduce tumorigenesis in Apc min/+ mice. Gut; 2009 Jun;58(6):805-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To determine if Mthfr deficiency and low dietary folate influence tumorigenesis in mice genetically predisposed to form numerous intestinal adenomas (Apc(min/+)).
  • RESULTS: Apc(min/+) mice fed high folate diets from weaning developed more adenomas than those fed the folic acid-deficient diet (FADD) or the control diet (CD); Mthfr deficiency did not affect adenoma number.
  • However, when the FADD and CD were administered to dams prior to conception, throughout pregnancy and continued in offspring post-weaning, Apc(min/+) offspring fed FADD developed fewer adenomas than those fed CD.
  • Mthfr(+/-) genotype of the mother or of the offspring also reduced adenoma numbers in the Apc(min/+) offspring.
  • Adenoma number was inversely correlated with plasma homocysteine (r = -0.49, p<0.005, intestinal dUTP/dTTP ratios (r = -0.42, p = 0.05), and levels of intestinal apoptosis (r = -0.36, p = 0.08).
  • CONCLUSIONS: Low dietary folate and Mthfr deficiency reduce adenoma formation in mice predisposed to tumorigenesis, possibly through increased apoptosis consequent to hyperhomocysteinaemia and nucleotide imbalances.
  • [MeSH-major] Adenoma / pathology. Adenomatous Polyposis Coli Protein / genetics. Colorectal Neoplasms / pathology. Diet. Folic Acid / administration & dosage. Methylenetetrahydrofolate Reductase (NADPH2) / deficiency
  • [MeSH-minor] Animals. Apoptosis. DNA Methylation. Female. Genetic Predisposition to Disease. Genotype. Homocysteine / blood. Male. Mice. Mice, Inbred C57BL. Mice, Mutant Strains. Pregnancy. Prenatal Nutritional Physiological Phenomena. Random Allocation. Thymine Nucleotides / analysis. Uridine Triphosphate / analysis. Weaning

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Folic Acid.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FOLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19174418.001).
  • [ISSN] 1468-3288
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adenomatous Polyposis Coli Protein; 0 / Thymine Nucleotides; 0LVT1QZ0BA / Homocysteine; 935E97BOY8 / Folic Acid; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2); QOP4K539MU / thymidine 5'-triphosphate; UT0S826Z60 / Uridine Triphosphate
  •  go-up   go-down


32. Nowak M, Madej J, Dziegiel P, Lopuszynski W, Rodo A, Ugorski M: Tumor-associated carbohydrate antigens: Sialyl Lea and T/Tn antigens in canine mammary tumors. Vet Pathol; 2009 Mar;46(2):222-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-associated carbohydrate antigens: Sialyl Lea and T/Tn antigens in canine mammary tumors.
  • Twenty-eight canine mammary tubulopapillary carcinomas and 14 simple adenomas were studied by immunohistochemistry for the expressions of the tumor-associated carbohydrate antigens.
  • Sialyl Le(a) was detected in 71.42% of the malignant and 92.84% of the benign tumors.
  • In contrast, 50% of the adenomas did not express T antigen, and 42.85% of them were only weakly stained for this carbohydrate structure.
  • Comparison of average values of reaction intensity (IRS) scale for malignant versus benign tumors by the Mann-Whitney U-test revealed a significant relationship between T and Tn antigens expression and type (malignant vs. benign) mammary tumors.
  • Based on the results obtained, it is suggested that each of the studied antigens can be treated as a tumor-associated antigen of canine mammary tumors.
  • However, only the T and Tn antigens seem to be associated with malignant transformation of mammary gland cells and to be of potential value as diagnostic markers.
  • [MeSH-major] Antigens, Tumor-Associated, Carbohydrate / metabolism. Dog Diseases / metabolism. Gangliosides / metabolism. Mammary Neoplasms, Animal / metabolism
  • [MeSH-minor] Adenoma / metabolism. Adenoma / veterinary. Animals. Biomarkers, Tumor / metabolism. Carcinoma / classification. Carcinoma / metabolism. Carcinoma / veterinary. Dogs. Female. Mammary Glands, Animal / cytology. Mammary Glands, Animal / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19261632.001).
  • [ISSN] 0300-9858
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Biomarkers, Tumor; 0 / Gangliosides; 0 / sialosyl-Tn antigen; 91847-18-6 / sialyl Le(a) ganglioside
  •  go-up   go-down


33. Lumachi F, Borsato S, Tregnaghi A, Marino F, Fassina A, Zucchetta P, Marzola MC, Cecchin D, Bui F, Iacobone M, Favia G: High risk of malignancy in patients with incidentally discovered adrenal masses: accuracy of adrenal imaging and image-guided fine-needle aspiration cytology. Tumori; 2007 May-Jun;93(3):269-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS AND BACKGROUND: The incidental finding of nonfunctioning adrenal masses (incidentalomas) is common, but no reliable criteria in differentiating between benign and malignant adrenal masses have been defined.
  • RESULTS: The revised final pathology showed 30 (71.4%) benign (26 adrenocortical adenomas, of which 3 were atypical, 2 ganglioneuromas, and 2 nonfunctioning benign pheochromocytomas) and 12 (28.6%, 95% CI = 15-42) adrenal malignancies (8 adrenocortical carcinomas and 4 unsuspected adrenal metastases).
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Biopsy, Fine-Needle. Incidental Findings. Magnetic Resonance Imaging
  • [MeSH-minor] 19-Iodocholesterol / analogs & derivatives. Adrenal Gland Diseases / diagnosis. Adrenal Gland Diseases / diagnostic imaging. Adrenal Gland Diseases / metabolism. Adrenal Gland Diseases / pathology. Adrenal Gland Diseases / surgery. Adrenalectomy. Adrenocortical Adenoma / diagnosis. Adrenocortical Adenoma / diagnostic imaging. Adrenocortical Adenoma / metabolism. Adrenocortical Adenoma / pathology. Adrenocortical Adenoma / surgery. Adrenocortical Carcinoma / diagnosis. Adrenocortical Carcinoma / diagnostic imaging. Adrenocortical Carcinoma / metabolism. Adrenocortical Carcinoma / pathology. Adrenocortical Carcinoma / surgery. Adult. Aged. Aldosterone / blood. Epinephrine / urine. Female. Ganglioneuroma / diagnosis. Ganglioneuroma / diagnostic imaging. Ganglioneuroma / metabolism. Ganglioneuroma / pathology. Ganglioneuroma / surgery. Humans. Hydrocortisone / blood. Iodine Radioisotopes. Laparoscopy. Male. Middle Aged. Norepinephrine / urine. Pheochromocytoma / diagnosis. Pheochromocytoma / diagnostic imaging. Pheochromocytoma / metabolism. Pheochromocytoma / pathology. Pheochromocytoma / surgery. Predictive Value of Tests. Prospective Studies. Radiography, Abdominal. Renin / blood. Sensitivity and Specificity. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. Norepinephrine .
  • Hazardous Substances Data Bank. EPINEPHRINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17679462.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 30461-91-7 / 19-Iodocholesterol; 4964P6T9RB / Aldosterone; 6B3QJ94C7P / 6-iodomethylcholesterol; EC 3.4.23.15 / Renin; WI4X0X7BPJ / Hydrocortisone; X4W3ENH1CV / Norepinephrine; YKH834O4BH / Epinephrine
  •  go-up   go-down


34. Matsuno A: [Recent trends in the pathophysiology and treatment of pituitary adenomas]. Brain Nerve; 2009 Aug;61(8):957-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Recent trends in the pathophysiology and treatment of pituitary adenomas].
  • The patterns of cytodifferentiation are closely related to the pathogenesis of pituitary adenomas.
  • Meanwhile, the role of hypothalamic hormones in the development of pituitary adenomas has recently attracted the attention of investigators.
  • The expression of growth hormone-releasing hormone and corticotrophin releasing hormone in corticotroph adenomas have been demonstrated in somatotroph adenomas and corticotropin adenomas, respectively.
  • This finding indicates that the endogenous expression of hypothalamic hormones and their receptors in human pituitary adenoma cells has ample significance in the autocrine or paracrine regulation of pituitary hormone production and tumor extension induced by hypothalamic hormones produced by adenoma cells.
  • The recent progress in surgical techniques for treatment of pituitary adenomas has provided several alternatives: transsphenoidal surgery vs. transcranial surgery, sublabial approach vs. endonasal approach, and microsurgery vs. endoscopic surgery.
  • There have also been developments in the medical treatment of pituitary adenomas.
  • The frequently used dopamine agonist, cabergoline, is very effective for treating prolactin-producing adenoma.
  • Long-acting octreotide and pegvisomant are now available for the treatment of growth hormone producing adenoma.
  • Cabergoline is also used for growth hormone producing adenoma.
  • Temozolomide has recently been used for atypical adenomas or pituitary carcinomas.
  • Adult growth hormone deficiency sometimes occurs in postoperative patients with pituitary adenomas.
  • [MeSH-major] Adenoma / etiology. Adenoma / therapy. Pituitary Neoplasms / etiology. Pituitary Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19697885.001).
  • [ISSN] 1881-6096
  • [Journal-full-title] Brain and nerve = Shinkei kenkyū no shinpo
  • [ISO-abbreviation] Brain Nerve
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Ergolines; 0 / Hypothalamic Hormones; 0 / Receptors, Neuropeptide; 0 / Receptors, Pituitary Hormone-Regulating Hormone; 0 / pegvisomant; 0 / somatotropin releasing hormone receptor; 12629-01-5 / Human Growth Hormone; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; 9015-71-8 / Corticotropin-Releasing Hormone; 9034-39-3 / Growth Hormone-Releasing Hormone; LL60K9J05T / cabergoline; RWM8CCW8GP / Octreotide
  • [Number-of-references] 32
  •  go-up   go-down


35. Cincik H, Gungor A, Ertugrul E, Cekin E, Dogru S: Peripheral osteoma of the mandible mimicking a parotid mass. Eur Arch Otorhinolaryngol; 2007 Apr;264(4):429-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report the case of a peripheral osteoma mimicking a benign tumor in the left parotid gland of a 75-year-old woman.
  • The clinical presentation of the painless mass on the lateral surface of the mandibular ascending ramus was suggestive of a benign parotid tumor such as a pleomorphic adenoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Oral Maxillofac Surg. 2004 Apr;33(3):310-1 [15287318.001]
  • [Cites] Head Neck. 2003 Nov;25(11):946-52 [14603455.001]
  • [Cites] Arch Otolaryngol. 1979 Dec;105(12):706-9 [508196.001]
  • [Cites] J Oral Maxillofac Surg. 1994 May;52(5):467-70 [8169708.001]
  • [Cites] Minerva Stomatol. 2006 Apr;55(4):209-14 [16618995.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1995 Oct;80(4):378-9 [8521095.001]
  • [Cites] J Oral Maxillofac Surg. 1998 Dec;56(12):1446-9 [9846545.001]
  • [Cites] Otolaryngol Head Neck Surg. 1993 Mar;108(3):293-7 [8464644.001]
  • [Cites] J Craniomaxillofac Surg. 2005 Aug;33(4):276-81 [15979316.001]
  • [Cites] J Oral Maxillofac Surg. 2002 Nov;60(11):1299-301 [12420263.001]
  • [Cites] J Oral Surg. 1980 Jun;38(6):452-5 [6929330.001]
  • (PMID = 17091281.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


36. Syro LV, Scheithauer BW, Ortiz LD, Fadul CE, Horvath E, Rotondo F, Kovacs K: Effect of temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma. Hormones (Athens); 2009 Oct-Dec;8(4):303-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma.
  • The patient was a 70-year-old man with a recurrent pituitary tumor.
  • Three surgeries were performed but the tumor recurred.
  • Based on histologic, immunohistochemical and ultrastructural studies, the diagnosis of oncocytic gonadotrophic pituitary adenoma was made.
  • The tumor was a macroadenoma partly immunopositive for LH.
  • Following Temozolomide administration the MRI demonstrated significant tumor necrosis.
  • The present case indicates that benign, typically slow-growing pituitary adenomas of oncocytic gonadotrophic type may respond to Temozolomide even when the tumor consists of an admixture of MGMT immunopositive and immunonegative cells.
  • [MeSH-major] Adenoma / drug therapy. Antineoplastic Agents, Alkylating / therapeutic use. Dacarbazine / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy. Pituitary Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20045804.001).
  • [ISSN] 1109-3099
  • [Journal-full-title] Hormones (Athens, Greece)
  • [ISO-abbreviation] Hormones (Athens)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


37. Huang L, Wang X, Gong W, Huang Y, Jiang B: The comparison of the clinical manifestations and risk factors of colorectal cancer and adenomas: results from a colonoscopy-based study in southern Chinese. Int J Colorectal Dis; 2010 Nov;25(11):1343-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The comparison of the clinical manifestations and risk factors of colorectal cancer and adenomas: results from a colonoscopy-based study in southern Chinese.
  • This study aimed to compare the clinical manifestations and risk factors of CRC and adenomas in native patients of Guangzhou.
  • Data on demographic information, main clinical manifestations, results of endoscopies and pathology, and possible risk factors of colorectal tumor were collected.
  • Chi-square test and logistic regression were used to compare the clinical characteristics and risk factors for CRC and adenomas.
  • Older age [odds ratio (OR), 1.079; 95% confidence interval (CI), 1.065-1.093], smoking status (OR, 1.712; 95% CI, 1.158-2.531), BMI =18.5-24.9 and  ≥ 25.0 (OR, 2.384; 95% CI, 1.250-4.549; OR, 2.162; 95% CI, 1.044-4.478, respectively) were significant risk factors for advanced adenoma, while female (OR, 0.638; 95% CI, 0.429-0.949) and using aspirin (OR, 0.188; 95% CI, 0.042-0.845) were significant protective factors.
  • For southern Chinese the most important influential factors for colorectal tumor are age, smoking, drinking, nutritional state, DM, hypertension, and the use of aspirin.
  • [MeSH-major] Adenoma / pathology. Asian Continental Ancestry Group. Colonoscopy. Colorectal Neoplasms / pathology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Obes (Lond). 2008 Feb;32(2):304-14 [17878894.001]
  • [Cites] Am J Gastroenterol. 1996 Feb;91(2):287-91 [8607494.001]
  • [Cites] Br J Surg. 2002 Jul;89(7):845-60 [12081733.001]
  • [Cites] Cancer. 2006 Jul 1;107(1):28-36 [16721800.001]
  • [Cites] Lancet. 2003 May 3;361(9368):1496-501 [12737858.001]
  • [Cites] Zhonghua Yi Xue Za Zhi. 2007 Jul 24;87(28):1950-3 [17923029.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Apr;11(4):385-91 [11927499.001]
  • [Cites] Cancer. 1996 Sep 15;78(6):1187-94 [8826939.001]
  • [Cites] Dis Colon Rectum. 2008 Jan;51(1):56-61 [18030529.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Aug;7(8):661-6 [9718217.001]
  • [Cites] Public Health Nutr. 2006 Sep;9(6):755-62 [16925881.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):526-31 [17372248.001]
  • [Cites] Am J Epidemiol. 1998 Jul 1 ;148(1):4-16 [9663397.001]
  • [Cites] Am J Gastroenterol. 2003 Dec;98(12):2777-83 [14687832.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):883-90 [12621132.001]
  • [Cites] Cancer Detect Prev. 2008;32(1):33-8 [18400417.001]
  • [Cites] J Natl Cancer Inst. 1997 Oct 1;89(19):1406-22 [9326910.001]
  • [Cites] World J Gastroenterol. 2009 Nov 7;15(41):5141-8 [19891012.001]
  • [Cites] Cancer Causes Control. 1996 Mar;7(2):253-63 [8740738.001]
  • [Cites] J Natl Cancer Inst. 2007 Nov 21;99(22):1729-35 [18000222.001]
  • [Cites] Lancet. 2007 May 12;369(9573):1603-13 [17499602.001]
  • [Cites] Br J Cancer. 2004 Jun 1;90(11):2157-66 [15150609.001]
  • [Cites] Zhonghua Liu Xing Bing Xue Za Zhi. 2004 Mar;25(3):265-8 [15200945.001]
  • [Cites] Ann Med. 1994 Dec;26(6):443-52 [7695871.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Sep;10(9):937-41 [11535544.001]
  • [Cites] Clin Gastroenterol Hepatol. 2003 Mar;1(2):96-102 [15017501.001]
  • [Cites] Gastroenterology. 2007 Oct;133(4):1077-85 [17698067.001]
  • [Cites] Int J Cancer. 2006 Aug 1;119(3):630-5 [16496385.001]
  • [Cites] Lancet Oncol. 2005 Nov;6(11):871-6 [16257795.001]
  • [Cites] Gastroenterology. 1994 Oct;107(4):1183-8 [7926468.001]
  • [Cites] Jpn J Cancer Res. 1999 Aug;90(8):805-11 [10543250.001]
  • [Cites] Dis Colon Rectum. 1999 Mar;42(3):337-42 [10223753.001]
  • [Cites] JAMA. 2005 Aug 24;294(8):914-23 [16118381.001]
  • [Cites] Br J Cancer. 1998;77(1):174-9 [9459165.001]
  • [Cites] Med Sci Sports Exerc. 2008 Feb;40(2):303-7 [18202571.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Dec;15(12):2391-7 [17164361.001]
  • [Cites] Cancer Causes Control. 1994 May;5(3):215-20 [8061168.001]
  • [Cites] J Am Coll Cardiol. 2007 Nov 20;50(21):2085-92 [18021879.001]
  • [Cites] World J Gastroenterol. 2003 Nov;9(11):2400-3 [14606064.001]
  • [Cites] N Engl J Med. 1996 Jan 11;334(2):82-7 [8531963.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Jul;11(7):622-9 [12101109.001]
  • [Cites] Cancer Causes Control. 2003 Nov;14(9):879-87 [14682445.001]
  • [Cites] Am J Epidemiol. 1998 Apr 1;147(7):670-80 [9554606.001]
  • [Cites] Annu Rev Nutr. 1999;19:545-86 [10448536.001]
  • [Cites] Med Sci Sports Exerc. 2003 Aug;35(8):1381-95 [12900694.001]
  • [Cites] Gastroenterology. 2008 Feb;134(2):617-9 [18242224.001]
  • [Cites] JAMA. 2007 Sep 26;298(12):1412-9 [17895457.001]
  • [Cites] Eur J Cancer Prev. 2007 Apr;16(2):102-7 [17297385.001]
  • [Cites] Nutr Cancer. 2001;39(1):50-7 [11588902.001]
  • [Cites] Ann Epidemiol. 1993 May;3(3):239-44 [8275195.001]
  • [Cites] JAMA. 2005 Jul 6;294(1):47-55 [15998890.001]
  • [Cites] N Engl J Med. 2005 May 19;352(20):2061-8 [15901859.001]
  • (PMID = 20680303.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


38. Kumar SM: Photoselective vaporization of the prostate: a volume reduction analysis in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia and carcinoma of the prostate. J Urol; 2005 Feb;173(2):511-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photoselective vaporization of the prostate: a volume reduction analysis in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia and carcinoma of the prostate.
  • PURPOSE: In this study preoperative and postoperative transrectal ultrasound prostate volume was evaluated in patients undergoing photoselective vaporization of prostate using an 80 W potassium-titanyl-phosphate (KTP) laser (Greenlight PV Laser System, Laserscope, San Jose, California) for obstructive uropathy secondary to benign prostatic hyperplasia or carcinoma of the prostate.
  • MATERIALS AND METHODS: A total of 18 patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia (8) and carcinoma of the prostate (10) were treated with an 80 W quasicontinuous KTP laser.
  • The end point of treatment was complete vaporization of the obstructive adenoma to the level of the capsular fibers and the creation of an adequate transurethral resection-like prostatic cavity.
  • CONCLUSIONS: Photoselective prostate vaporization can effectively vaporize obstructive benign and malignant prostatic tissue, leading to a significant decrease in the total volume of the treated prostate (p = 0.000).


39. Tijhuis MJ, Wark PA, Aarts JM, Visker MH, Nagengast FM, Kok FJ, Kampman E: GSTP1 and GSTA1 polymorphisms interact with cruciferous vegetable intake in colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev; 2005 Dec;14(12):2943-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GSTP1 and GSTA1 polymorphisms interact with cruciferous vegetable intake in colorectal adenoma risk.
  • The possible interplay between cruciferous vegetable consumption, functional genetic variations in glutathione S-transferases (GST) M1, T1, P1, and A1, and colorectal adenomas, was investigated in a Dutch case-control study.
  • The GSTM1 and GSTT1 deletion polymorphisms, and the single nucleotide polymorphisms in GSTP1 (A313G) and in GSTA1 (C-69T) were assessed among 746 cases who developed colorectal adenomas and 698 endoscopy-based controls without any type of colorectal polyps.
  • High consumption was slightly positively associated with colorectal adenomas [odds ratio (OR) 1.15; 95% confidence interval, 0.92-1.44].
  • The GSTM1 and GSTT1 genotypes did not seem to modify the association between cruciferous vegetable intake and colorectal adenomas.
  • In conclusion, GSTP1 and GSTA1 genotypes might modulate the association between cruciferous vegetable intake and colorectal adenomas.
  • [MeSH-major] Adenoma / enzymology. Adenoma / genetics. Colorectal Neoplasms / enzymology. Colorectal Neoplasms / genetics. Glutathione S-Transferase pi / genetics. Glutathione Transferase / genetics. Polymorphism, Genetic. Vegetables
  • [MeSH-minor] Biomarkers, Tumor / genetics. Case-Control Studies. Chi-Square Distribution. Female. Humans. Logistic Models. Male. Middle Aged. Netherlands. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16365014.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.5.1.- / glutathione S-transferase T1; EC 2.5.1.18 / Glutathione S-Transferase pi; EC 2.5.1.18 / Glutathione Transferase
  •  go-up   go-down


40. Galitskiĭ MV, Khomeriki SG, Nikiforov PA: [Expression of proliferation and apoptosis markers in neoplasms of colon mucosa after cholecystectomy]. Eksp Klin Gastroenterol; 2009;(5):28-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The goal of the study was to investigate immunohistochemical markers of proliferation and apoptosis in colorectal adenomas and adenocarcinomas at the patients with cholecystectomy.
  • Fifty patients (40 with retained function of gallbladder and 10 patients with cholecystectomy) histologically diagnosed as proximal colon adenoma or adenocarcinoma were included into the study.
  • Colonoscopic biopsies have been taken from the lesion in cancer patients, and colonoscopic polypectomy has been performed for adenomas.
  • No significant difference was detected in the comparison of Ki-67 expression levels between the healthy mucosa and adenomas at the patients with cholecystectomy 43,4 +/- 3,45 (p > 0,05), but more prominent increase was revealed in adenocarcinomas 64,33 +/- 7,67% (p < 0,01).
  • At the patients without cholecystectomy the frequency of revealing p53 in adenomas does not vary, compared with healthy mucosa, however in adenocarcinomas p53 was not revealed at none case.
  • As a contrast, in group of the patients with cholecystectomy the frequency of revealing p53 in adenomas is considerably increased (up to 80%), and even in adenocarcinomas, p53 was revealed in 30,8% of cases.
  • Thus, in benign colorectal tumors at the patients with retained function of gallbladder intensifying of epithelial cells proliferation is not accompanied with intensifying of apoptosis, and in malignant tumors a complete supression of apoptosis is observed.
  • At the patients with a cholecystectomy, the increase of proliferative activity is accompanied by increased apoptosis in adenomas and maintained apoptosis in adenocarcinomas.
  • [MeSH-major] Apoptosis. Biomarkers, Tumor / biosynthesis. Cell Proliferation. Cholecystectomy. Colon / metabolism. Colonic Neoplasms / metabolism. Gene Expression Regulation, Neoplastic. Intestinal Mucosa / metabolism. Ki-67 Antigen / biosynthesis. Tumor Suppressor Protein p53 / biosynthesis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20205327.001).
  • [ISSN] 1682-8658
  • [Journal-full-title] Ėksperimental'nai︠a︡ i klinicheskai︠a︡ gastroėnterologii︠a︡ = Experimental & clinical gastroenterology
  • [ISO-abbreviation] Eksp Klin Gastroenterol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


41. Yu R, Nissen NN, Dhall D, Wei M: Pheochromocytoma in patients suspected of harboring adrenal metastasis: management and clinical predictors. Endocr Pract; 2008 Nov;14(8):967-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pathologic diagnosis, demographic data, clinical history, imaging studies, and laboratory test results were reviewed and compared among patients whose adrenal mass was determined to be metastasis, adenoma, or pheochromocytoma.
  • Of the adrenal masses, 18 (60%) were metastases, 8 (27%) were benign adenomas, and 4 (13%) were pheochromocytomas.
  • Adrenal biopsy was performed without biochemical testing for pheochromocytoma in 9 patients (30%), including 2 subsequently found to have this tumor.
  • Clinical parameters were similar among patients with metastasis, adenoma, or pheochromocytoma.
  • CONCLUSIONS: Pheochromocytoma occurs frequently in patients suspected of harboring adrenal metastasis, but this tumor is often not considered in clinical practice.
  • [MeSH-major] Adrenal Gland Neoplasms / pathology. Pheochromocytoma / pathology

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19095594.001).
  • [ISSN] 1934-2403
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Strunk H, Börner N, Stuckmann G, Fröhlich E, Hadizadeh D: [Contrast-enhanced "low MI real-time" sonography for the assessment of the malignancy of focal liver lesions]. Rofo; 2005 Oct;177(10):1394-404
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor size was between 8 mm and 14.5 cm.
  • One of the malignant lesions was classified as benign.
  • Of the 25 benign lesions, 21 could be classified correctly as benign, however, 4 lesions (2 hemangiomas, 1 adenoma, 1 teratoma) showed no enhancement in the portal and late phase and were incorrectly classified as malignant as well.
  • CONCLUSION: Using pulse-inversion harmonic US with SonoVue, liver lesions showing an isoechoic or hyperechoic enhancement can be classified as probably benign.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. SULFUR HEXAFLUORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16170709.001).
  • [ISSN] 1438-9029
  • [Journal-full-title] RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin
  • [ISO-abbreviation] Rofo
  • [Language] ger
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Phospholipids; 0 / contrast agent BR1; WS7LR3I1D6 / Sulfur Hexafluoride
  •  go-up   go-down


43. Metzler M, Luedecke DK, Saeger W, Grueters A, Haberl H, Kiess W, Repp R, Rascher W, Doetsch J: Low prevalence of Gs alpha mutations in śomatotroph adenomas of children and adolescents. Cancer Genet Cytogenet; 2006 Apr 15;166(2):146-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low prevalence of Gs alpha mutations in śomatotroph adenomas of children and adolescents.
  • Mutations in the gene coding for the alpha-subunit of the heterotrimeric stimulatory G protein Gs are the most frequently identified molecular events in the development of somatotroph adenomas in adults.
  • In children and adolescents, somatotroph adenomas are rare, and only two cases with the Gs alpha mutation have been reported so far.
  • In this study, we therefore investigated the prevalence of activating Gs alpha mutations in 17 patients younger than 20 years with pituitary growth hormone-secreting adenomas and examined the characteristics of mutation-positive cases.
  • Interestingly, in contrast to the remaining cases, the adenomas positive for the Gs alpha mutation proved to be nonsporadic, but part of a syndrome associated with endocrine tumors in both individuals.
  • Additional tests confirmed McCune-Albright syndrome in the first patient and multiple endocrine neoplasia type 1 syndrome in the second patient.
  • In contrast to the findings in adult cases, somatotroph adenomas in young patients seem to carry somatic Gs alpha mutations at a lower frequency, and germ-line or early postzygotic mutational events may be responsible for the shortened latency of tumorigenesis.
  • [MeSH-major] GTP-Binding Protein alpha Subunits, Gs / genetics. Growth Hormone-Secreting Pituitary Adenoma / genetics. Mutation / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16631471.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.6.5.1 / GTP-Binding Protein alpha Subunits, Gs
  •  go-up   go-down


44. Hsieh MS, Liu KL, Tien YW, Shun CT: Combined pancreatic endocrine tumor and serous cystadenoma. J Formos Med Assoc; 2009 Sep;108(9):739-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined pancreatic endocrine tumor and serous cystadenoma.
  • The combination of pancreatic serous cystadenoma and endocrine tumor is even rarer.
  • Here, we report two cases of combined pancreatic serous adenoma and endocrine tumor.
  • One was a 64-year-old woman with serous cystadenoma and pancreatic endocrine tumor.
  • The other case was a 28-year-old woman with von Hippel-Lindau disease with combined pancreatic serous oligocystic adenoma and well-differentiated malignant endocrine carcinoma.
  • Careful examination of benign serous cystadenoma should be kept in mind during clinical practice, to rule out the possibility of combined malignant endocrine tumor.
  • In addition, von Hippel-Lindau disease should also be suspected when a young adult presents with combination of pancreatic serous cystadenoma and endocrine tumor.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19773214.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Singapore
  • [Number-of-references] 15
  •  go-up   go-down


45. Kim JH, Kim JH, Han JH, Yoo BM, Kim MW, Kim WH: Is endoscopic papillectomy safe for ampullary adenomas with high-grade dysplasia? Ann Surg Oncol; 2009 Sep;16(9):2547-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is endoscopic papillectomy safe for ampullary adenomas with high-grade dysplasia?
  • OBJECTIVES: This study was designed to provide safe management guidelines for ampullary adenoma by analysis of clinicopathological features.
  • BACKGROUND: The treatment of ampullary cancer has been established; however, the indications for treatment of ampullary adenoma remain controversial.
  • METHODS: Between July 1997 and July 2008, a total of 33 patients were diagnosed with ampullary adenoma prior to procedures: 20 endoscopic papillectomies (ESP), 5 transduodenal resections (TDR), and 8 pancreatoduodenectomies (PD).
  • The size of tumor by final pathology was 1.27 +/- 0.89 cm in LGD, 1.81 +/- 0.99 cm in HGD, and 1.98 +/- 1.08 cm in cancer group.
  • There was a significant correlation between size of tumor and final pathology (P = 0.036).
  • According to receiver operating characteristic (ROC) curve, criterion to predict HGD/cancer was tumor size larger than 1.5 cm; sensitivity and specificity were 55.6% and 80.0%, respectively, and likelihood ratio was 2.778.
  • However, size of tumor was not associated with preprocedural pathology.
  • CONCLUSIONS: Ampullary adenoma with preprocedural HGD was highly associated with coexistence of cancer and recurrence.
  • Therefore, we suggest that ampullary adenoma with preprocedural HGD or more than 1.5 cm should not be managed with endoscopic papillectomy due to high associated rates of recurrence.
  • [MeSH-major] Adenoma / surgery. Ampulla of Vater / surgery. Common Bile Duct Neoplasms / surgery. Endoscopy, Gastrointestinal
  • [MeSH-minor] Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Pancreaticoduodenectomy. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19568817.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Neuzillet Y, Lechevallier E, André M, de Fromont M, Nahon O, Coulange C: [Renal oncocytoma associated with renal cell carcinoma]. Prog Urol; 2005 Apr;15(2):312-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Renal oncocytoma is a benign tumour that can be associated with renal cell carcinoma in rare genetic syndromes.
  • The authors report the case of a 62-year-old patient with no medical history, in whom assessment of low back pain in 1999 demonstrated a 40 mm tumour of the lower pole of the left kidney.
  • [MeSH-major] Adenoma, Oxyphilic / diagnosis. Carcinoma, Renal Cell / diagnosis. Kidney Neoplasms / diagnosis. Neoplasms, Multiple Primary / diagnosis

  • Genetic Alliance. consumer health - Oncocytoma renal.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15999615.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


47. Torer N, Torun D, Torer N, Micozkadioglu H, Noyan T, Ozdemir FN, Haberal M: Predictors of early postoperative hypocalcemia in hemodialysis patients with secondary hyperparathyroidism. Transplant Proc; 2009 Nov;41(9):3642-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We recorded preoperative adjusted serum calcium (Ca(+2)), phosphate, alkaline phosphatase, intact parathyroid hormone, and hemoglobin levels; mean systolic and diastolic blood pressure levels; parathyroid ultrasonography and scintigraphic data; and number and weight of the resected adenomas.
  • Age (36.0 +/- 9.7 vs 49.2 +/- 16.6 years; P = .006); levels of preoperative serum Ca(+2) (9.6 +/- 0.7 vs 10.4 +/- 1.1 mg/dL; P = .01), alkaline phosphatase (346.7 +/- 354.7 vs 653.3 +/- 553.7 mg/dL; P = .05), and hemoglobin (10.5 +/- 1.4 vs 12.3 +/- 2.5 g/dL; P = .009); and number (2.0 +/- 1.3 vs 2.9 +/- 0.9; P = .04) and weight (1.9 +/- 2.1 vs 3.2 +/- 1.7; P = .01) of excised parathyroid adenomas were significantly lower among the hypocalcemia than the normocalcemia group.
  • Among hemodialysis patients with secondary hyperparathyroidism, age, levels of preoperative serum Ca(+2) and alkaline phosphatase, and number and weight of adenomas were associated with early development of postoperative hypocalcemia.

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Dialysis.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19917359.001).
  • [ISSN] 1873-2623
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hemoglobins; EC 3.1.3.1 / Alkaline Phosphatase; SY7Q814VUP / Calcium
  •  go-up   go-down


48. Iizuka H, Okamura S, Onozato Y, Ishihara H, Kakizaki S, Mori M: Endoscopic submucosal dissection for colorectal tumors. Gastroenterol Clin Biol; 2009 Oct-Nov;33(10-11):1004-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EMR was used in the majority of adenomas, and showed high rates of both one-piece resection (OPR) and complete resection (CR) for adenomas less than 20 mm.
  • However, for adenomas and cancers greater or equal to 20 mm, the CR rate for EMR was significantly lower than that for ESD because of the incidence of OPR with a positive lateral margin (16% vs 0% with ESD vs EMR).
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adenoma / pathology. Adenoma / surgery. Adult. Aged. Aged, 80 and over. Female. Humans. Intestinal Perforation / etiology. Male. Middle Aged. Outcome Assessment (Health Care). Retrospective Studies. Risk Factors. Time Factors

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19762190.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] France
  •  go-up   go-down


49. Wang TD, Friedland S, Sahbaie P, Soetikno R, Hsiung PL, Liu JT, Crawford JM, Contag CH: Functional imaging of colonic mucosa with a fibered confocal microscope for real-time in vivo pathology. Clin Gastroenterol Hepatol; 2007 Nov;5(11):1300-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & AIMS: Histologic interpretation of disease currently is performed with static images of excised tissues, and is limited by processing artifact, sampling error, and interpretive variability.
  • The aim of this study was to show the use of functional optical imaging of viable mucosa for quantitative evaluation of colonic neoplasia in real time.
  • RESULTS: Normal mucosa showed circular crypts with uniform size, hyperplasia revealed proliferative glands with serrated lumens, and adenomas displayed distorted elongated glands.
  • Passage of fluorescein through adenomatous mucosa was delayed substantially.
  • For t greater than 5 seconds, high sensitivity, specificity, and accuracy was achieved using a discriminant function to evaluate the contrast ratio to distinguish normal from lesional mucosa (91%, 87%, and 89%, respectively; P < .001), hyperplasia from adenoma (97%, 96%, and 96%, respectively; P < .001), and tubular from villous adenoma (100%, 92%, and 93%, respectively; P < .001).

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUORESCEIN .
  • Hazardous Substances Data Bank. D&C Yellow No. 8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Pharmacol. 2002 Jan 1;63(1):81-8 [11754877.001]
  • [Cites] Endoscopy. 2007 Feb;39 Suppl 1:E145 [17611888.001]
  • [Cites] Appl Opt. 2002 Jan 1;41(1):182-92 [11900434.001]
  • [Cites] Br J Nutr. 2003 May;89(5):639-47 [12720584.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6247-51 [15342411.001]
  • [Cites] Gastroenterology. 2004 Sep;127(3):706-13 [15362025.001]
  • [Cites] Hum Pathol. 1983 Nov;14(11):931-68 [6629368.001]
  • [Cites] Hum Pathol. 1988 Feb;19(2):166-78 [3343032.001]
  • [Cites] Appl Opt. 2004 Nov 1;43(31):5763-71 [15540433.001]
  • [Cites] J Vasc Res. 2004 Sep-Oct;41(5):400-11 [15467299.001]
  • [Cites] Gastroenterology. 2005 Jun;128(7):2119-23 [15940642.001]
  • [Cites] Gastrointest Endosc. 2005 Nov;62(5):686-95 [16246680.001]
  • [Cites] Cancer Immunol Immunother. 2006 Jan;55(1):47-55 [15868166.001]
  • [Cites] Radiology. 2006 Feb;238(2):405-22 [16436809.001]
  • [Cites] J Pharm Sci. 2006 Jun;95(6):1393-401 [16625653.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 May;4(5):566-72 [16630761.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 18;103(29):11003-8 [16835297.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Aug;4(8):979-87 [16843068.001]
  • [Cites] Biochem Pharmacol. 2006 Sep 14;72(6):729-38 [16844096.001]
  • [Cites] Endoscopy. 2006 Sep;38(9):886-90 [16981104.001]
  • [Cites] Nature. 2006 Oct 19;443(7113):765 [17051200.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Nov;4(11):1309-13 [17110299.001]
  • [Cites] Endoscopy. 2006 Nov;38(11):1110-4 [17111332.001]
  • [Cites] Neurosci Lett. 2007 Jan 3;411(1):1-5 [17110033.001]
  • [Cites] Am J Respir Crit Care Med. 2007 Jan 1;175(1):22-31 [17023733.001]
  • [Cites] Cell Tissue Res. 2007 Apr;328(1):77-84 [17165089.001]
  • [Cites] Gastrointest Endosc. 2007 Aug;66(2):398-99, discussion 400 [17521648.001]
  • [CommentIn] Clin Gastroenterol Hepatol. 2007 Nov;5(11):1259-60 [17936080.001]
  • (PMID = 17936692.001).
  • [ISSN] 1542-7714
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / K08 DK067618-04; United States / NIDDK NIH HHS / DK / K08 DK067618; United States / NCI NIH HHS / CA / U54 CA105296; United States / NIDDK NIH HHS / DK / K08 DK067618-05; United States / NIDDK NIH HHS / DK / DK067618-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; TPY09G7XIR / Fluorescein
  • [Other-IDs] NLM/ NIHMS34014; NLM/ PMC2104519
  •  go-up   go-down


50. Sansbury LB, Wanke K, Albert PS, Kahle L, Schatzkin A, Lanza E, Polyp Prevention Trial Study Group: The effect of strict adherence to a high-fiber, high-fruit and -vegetable, and low-fat eating pattern on adenoma recurrence. Am J Epidemiol; 2009 Sep 1;170(5):576-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of strict adherence to a high-fiber, high-fruit and -vegetable, and low-fat eating pattern on adenoma recurrence.
  • The authors examined the effect of strict adherence to a low-fat, high-fiber, high-fruit and -vegetable intervention over 4 years among participants (n = 1,905) in the US Polyp Prevention Trial (1991-1998) on colorectal adenoma recurrence.
  • Multivariate logistic regression models were used to estimate the association between dietary adherence and adenoma recurrence.
  • The authors observed a 35% reduced odds of adenoma recurrence among super compliers compared with controls (odds ratio = 0.65, 95% confidence interval: 0.47, 0.92).
  • Findings suggest that high compliance with a low-fat, high-fiber diet is associated with reduced risk of adenoma recurrence.
  • [MeSH-major] Adenoma / diet therapy. Colonic Neoplasms / diet therapy. Diet, Fat-Restricted. Dietary Fiber / administration & dosage. Neoplasm Recurrence, Local / prevention & control. Patient Compliance

  • MedlinePlus Health Information. consumer health - Dietary Fiber.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2000 Apr 20;342(16):1149-55 [10770979.001]
  • [Cites] Eur J Clin Nutr. 2009 Jun;63(6):707-17 [18685556.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Sep;9(9):869-73 [11008902.001]
  • [Cites] Lancet. 2000 Oct 14;356(9238):1300-6 [11073017.001]
  • [Cites] Eur J Cancer Prev. 2000 Oct;9(5):363-5 [11075890.001]
  • [Cites] Gastroenterology. 2001 Feb;120(2):387-91 [11159879.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 4;93(7):525-33 [11287446.001]
  • [Cites] Am J Clin Nutr. 2001 Sep;74(3):387-401 [11522565.001]
  • [Cites] N Engl J Med. 2003 Jun 26;348(26):2599-608 [12826634.001]
  • [Cites] Proc R Soc Med. 1971 Sep;64(9):964-5 [5114307.001]
  • [Cites] N Engl J Med. 1980 Oct 30;303(18):1038-41 [6999345.001]
  • [Cites] J Natl Cancer Inst. 1981 Jun;66(6):1191-308 [7017215.001]
  • [Cites] J Natl Cancer Inst. 1990 Apr 18;82(8):650-61 [2157027.001]
  • [Cites] J Clin Epidemiol. 1990;43(12):1327-35 [2254769.001]
  • [Cites] Stat Med. 1991 Oct;10(10):1595-605 [1947515.001]
  • [Cites] J Natl Cancer Inst. 1992 Dec 16;84(24):1887-96 [1334153.001]
  • [Cites] Stat Med. 1994 Nov 30;13(22):2323-35 [7855466.001]
  • [Cites] Ann Med. 1994 Dec;26(6):443-52 [7695871.001]
  • [Cites] J Clin Epidemiol. 1994 May;47(5):525-36 [7730878.001]
  • [Cites] J Natl Cancer Inst. 1995 Dec 6;87(23):1760-6 [7473832.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 May;5(5):375-83 [9162304.001]
  • [Cites] J Clin Pharmacol. 1997 Aug;37(8):667-72 [9378838.001]
  • [Cites] Cancer Causes Control. 1998 Aug;9(4):357-67 [9794167.001]
  • [Cites] Eur J Cancer Prev. 2005 Feb;14(1):21-9 [15677892.001]
  • [Cites] JAMA. 2006 Feb 8;295(6):643-54 [16467233.001]
  • [Cites] J Am Coll Nutr. 2006 Oct;25(5):370-81 [17031005.001]
  • [Cites] J Natl Cancer Inst. 2007 Oct 3;99(19):1471-83 [17895473.001]
  • [Cites] J Nutr. 2007 Nov;137(11):2443-50 [17951483.001]
  • [Cites] Cancer. 2007 Nov 15;110(10):2119-52 [17939129.001]
  • [Cites] Am J Epidemiol. 2008 Jul 1;168(1):38-48 [18525082.001]
  • [Cites] BMJ. 2008;337:a1344 [18786971.001]
  • [Cites] N Engl J Med. 2000 Apr 20;342(16):1156-62 [10770980.001]
  • (PMID = 19643809.001).
  • [ISSN] 1476-6256
  • [Journal-full-title] American journal of epidemiology
  • [ISO-abbreviation] Am. J. Epidemiol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2732986
  • [Investigator] Schatzkin A; Lanza E; Corle D; Freedman LS; Clifford C; Tangrea J; Cooper MR; Paskett E; Quandt S; DeGraffinreid C; Bradham K; Kent L; Self M; Boyles D; West D; Martin L; Taylor N; Dickenson E; Kuhn P; Harmon J; Richardson I; Lee H; Marceau E; Lance MP; Marshal JR; Hayes D; Phillips J; Petrelli N; Shelton P; Randall E; Blake A; Wodarski L; Deinzer M; Melton R; Iber FL; Murphy P; Bote EC; Brandt-Whittington L; Haroon N; Kazi N; Moore MA; Orloff SB; Ottosen WJ; Patel M; Rothschild RL; Ryan M; Sullivan JM; Caan B; Selby JV; Friedman G; Lawson M; Taff G; Snow D; Belfay M; Schoenberger M; Sampel K; Giboney T; Randel M; Shike M; Winawer S; Bloch A; Mayer J; Morse R; Latkany L; D'Amato D; Schaffer A; Cohen L; Weissfeld J; Schoen R; Schade RR; Kuller L; Gahagan B; Caggiula A; Lucas C; Coyne T; Pappert S; Robinson R; Landis V; Misko S; Search L; Burt RW; Slattery M; Viscofsky N; Benson J; Neilson J; McDivitt R; Briley M; Heinrich K; Samowitz W; KikendalL JW; Mateski DJ; Wong R; Stoute E; Jones-Miskovsky V; Greaser A; Hancock S; Chandler S; Cahill J; Hasson M; Daston C; Brewer B; Zimmerman T; Sharbaugh C; O'Brien B; Cranston L; Odaka N; Umbel K; Pinsky J; Price H; Slonim A; Lewin K; Appelman H; Bachorik PS; Lovejoy K; Sowell A; Greenberg ER; Feldman E; Garza C; Summers R; Weiand S; DeMets D
  •  go-up   go-down


51. Ide F, Tanaka A, Kusama K: Further evidence for adipocytic differentiation by the neoplastic myoepithelium. J Oral Pathol Med; 2007 Mar;36(3):187-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lipomatous pleomorphic adenoma (PA)/myoepithelioma is rare.
  • Nevertheless, adipocytic differentiation in salivary gland tumors is a well-known phenomenon.
  • As extensive lipometaplasia occurs primarily in adenomas with myoepithelial participation, circumstantial evidence implicates neoplastic myoepithelium (NME), especially the spindle type, as a key partaker.
  • We report here a unique PA that represents an equivocal transition from the epithelioid NME to adipocytes in recurrent lesions but not in a primary tumor.
  • [MeSH-major] Adenoma, Pleomorphic / pathology. Adipocytes / pathology. Epithelial Cells / pathology. Myoepithelioma / pathology. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Adult. Cell Differentiation. Humans. Male. Neoplasm Recurrence, Local

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17305642.001).
  • [ISSN] 0904-2512
  • [Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • [ISO-abbreviation] J. Oral Pathol. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


52. Hayashi S, Kitada M, Ozawa K, Sato K, Takamatsu M, Hirata S, Sasajima T: [Functional mediastinal parathyroid adenoma with cystic change; report of a case]. Kyobu Geka; 2010 Jul;63(7):599-601
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Functional mediastinal parathyroid adenoma with cystic change; report of a case].
  • We report a case of functional mediastinal parathyroid adenoma with cystic change.
  • Computed tomography (CT) revealed the shape of a cystic tumor with a diameter of 4 cm in the anterior mediastinum.
  • 99mTc-MIBI scintigraphy showed accumulation of the radioisotope in the tumor.
  • The patient was diagnosed as primary HPT caused by the cystic parathyroid adenoma.
  • The tumor was resected through a median sternotomy.
  • [MeSH-major] Adenoma / pathology. Parathyroid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20662244.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


53. Scarabin C, Koskas M, Bornes M, Azria E, Luton D: Gigantomastia and vulvar lactating adenoma in a patient with myasthenia during pregnancy. Am J Obstet Gynecol; 2010 Oct;203(4):e5-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gigantomastia and vulvar lactating adenoma in a patient with myasthenia during pregnancy.
  • We report the association of gigantomastia during pregnancy and a lactating adenoma in ectopic breast tissue of the vulva in a context of myasthenia in a 27-year-old primigravid woman.
  • [MeSH-major] Adenoma / diagnosis. Breast. Breast Diseases / diagnosis. Choristoma / diagnosis. Pregnancy Complications / diagnosis. Vulvar Diseases / diagnosis


54. Akin H, Gunluoglu Z, Kara V, Melek H, Dincer I: Mediastinal ectopic parathyroid adenoma: report of two cases successfully treated by VATS approach. Thorac Cardiovasc Surg; 2008 Feb;56(1):60-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mediastinal ectopic parathyroid adenoma: report of two cases successfully treated by VATS approach.
  • Ectopic parathyroid adenomas are the cause of approximately one in four cases of primary hyperparathyroidism (pHPT).
  • Most ectopic parathyroid adenomas are located adjacent to the upper thymus gland and can be resected with a collar incision.
  • In rare cases, however, adenomas located in the chest require a transsternalor transthoracic approach.
  • We present two cases with primary hyperparathyroidism due to mediastinal ectopic parathyroid adenoma that were successfully treated by VATS approach.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18200473.001).
  • [ISSN] 0171-6425
  • [Journal-full-title] The Thoracic and cardiovascular surgeon
  • [ISO-abbreviation] Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


55. Lupi I, Manetti L, Caturegli P, Menicagli M, Cosottini M, Iannelli A, Acerbi G, Bevilacqua G, Bogazzi F, Martino E: Tumor infiltrating lymphocytes but not serum pituitary antibodies are associated with poor clinical outcome after surgery in patients with pituitary adenoma. J Clin Endocrinol Metab; 2010 Jan;95(1):289-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor infiltrating lymphocytes but not serum pituitary antibodies are associated with poor clinical outcome after surgery in patients with pituitary adenoma.
  • CONTEXT: Serum pituitary antibodies (Pit Abs) and tumor-infiltrating lymphocytes (TILs) have been described in pituitary adenomas, but their clinical significance remains unknown.
  • OBJECTIVE: The objective of the study was to assess Pit Abs and TILs prevalence in pituitary adenomas and their influence on clinical outcome.
  • PATIENTS AND SETTING: Two hundred ninety-one pituitary adenoma cases (110 non-secreting, 30 ACTH-69 GH-71 prolactin- and 13 TSH-secreting adenoma; 177 operated and 114 untreated), 409 healthy controls, and 14 autoimmune hypophysitis were enrolled in a tertiary referral center.
  • The presence of TILs was evaluated using CD45 staining in a subset of adenomas surgically treated (n = 72).
  • MAIN OUTCOME MEASURE: Clinical response of pituitary adenoma after surgery was evaluated.
  • RESULTS: Pit Abs prevalence was higher in adenomas (5.1%) than healthy subjects (0.7%, P < 0.0001) and lower than in autoimmune hypophysitis patients (57%, P < 0.0001).
  • Similarly, TILs prevalence was higher in adenomas than normal pituitary (P = 0.01) and lower than in autoimmune hypophysitis (P < 0.0001).
  • A poor clinical outcome was more common in adenoma patients with TILs (11 of 18, 61%) than in those without (17 of 54, 31%, P = 0.026).
  • Multivariate regression analysis identified the presence of TILs as independent prognostic factor for persistence/recurrence of pituitary adenoma.
  • CONCLUSIONS: TILs and Pit Abs are present in a significant number of pituitary adenoma patients.
  • Cell-mediated immunity appears to be predictive of a less favorable clinical outcome.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Horm Res. 2001;55(6):288-92 [11805433.001]
  • [Cites] Pituitary. 2011 Dec;14(4):388-94 [19466616.001]
  • [Cites] Eur J Cancer. 2002 Oct;38(15):2014-9 [12376206.001]
  • [Cites] J Endocrinol. 2002 Nov;175(2):417-23 [12429039.001]
  • [Cites] Eur J Endocrinol. 2002 Dec;147(6):767-75 [12457452.001]
  • [Cites] N Engl J Med. 2003 Jan 16;348(3):203-13 [12529460.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Feb;88(2):650-4 [12574195.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8372-7 [12826605.001]
  • [Cites] Endocr J. 2003 Dec;50(6):697-702 [14709840.001]
  • [Cites] Endocrine. 2003 Dec;22(3):335-40 [14709807.001]
  • [Cites] Lancet. 1987 Jun 20;1(8547):1394-8 [2884495.001]
  • [Cites] J Clin Endocrinol Metab. 1988 Oct;67(4):633-8 [3417843.001]
  • [Cites] J Endocrinol Invest. 1991 Sep;14(8):691-6 [1774454.001]
  • [Cites] Clin Endocrinol (Oxf). 1993 May;38(5):495-500 [8080469.001]
  • [Cites] Acta Neurochir (Wien). 1994;126(1):38-43 [8154320.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Dec;80(12):3421-4 [8530576.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Feb;83(2):609-18 [9467582.001]
  • [Cites] J Lab Clin Med. 1998 Jul;132(1):25-31 [9665368.001]
  • [Cites] Endocr J. 1998 Jun;45(3):357-61 [9790270.001]
  • [Cites] Endocr Rev. 2005 Aug;26(5):599-614 [15634713.001]
  • [Cites] J Neurosurg. 2006 Aug;105(2):309-14 [17219839.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Feb;92(2):604-7 [17090639.001]
  • [Cites] Neurol Med Chir (Tokyo). 2007 Mar;47(3):136-9 [17384498.001]
  • [Cites] J Thorac Oncol. 2006 Jul;1(6):513-9 [17409910.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Jun;92(6):2176-81 [17341554.001]
  • [Cites] Ann N Y Acad Sci. 2007 Jun;1107:129-35 [17804540.001]
  • [Cites] J Endocrinol Invest. 2007 Sep;30(8):677-83 [17923800.001]
  • [Cites] Neurosurg Rev. 2008 Apr;31(2):157-63 [18253771.001]
  • [Cites] Endocr J. 2000 Aug;47(4):407-16 [11075721.001]
  • [Cites] Immunol Rev. 2008 Apr;222:101-16 [18363996.001]
  • [Cites] Immunol Rev. 2008 Apr;222:328-40 [18364012.001]
  • [Cites] Arch Immunol Ther Exp (Warsz). 2008 May-Jun;56(3):181-91 [18512029.001]
  • [Cites] Clin Endocrinol (Oxf). 2008 Aug;69(2):269-78 [18194487.001]
  • [Cites] Endocr J. 2008 Aug;55(4):729-35 [18497455.001]
  • [Cites] Am J Surg Pathol. 2008 Nov;32(11):1661-6 [18753941.001]
  • [Cites] Histochem Cell Biol. 2008 Dec;130(6):1079-90 [18953558.001]
  • [Cites] Cancer Immun. 2008;8:16 [19053167.001]
  • [Cites] Cancer Lett. 2009 Jun 18;278(2):123-9 [18930343.001]
  • [Cites] No Shinkei Geka. 2002 Jan;30(1):95-9 [11806114.001]
  • (PMID = 19875479.001).
  • [ISSN] 1945-7197
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R21 DK080351; United States / NIDDK NIH HHS / DK / DK080351
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Biomarkers
  • [Other-IDs] NLM/ PMC2805498
  •  go-up   go-down


56. Andía Melero VM, García Centeno R, Fernández JB, Vigovich C, Sánchez García-Cervigón P, Jara Albarrán A: [Feminizing adrenal tumours in Spain: report of a case and review of the five previously published patients]. Endocrinol Nutr; 2009 Nov;56(9):470-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Feminizing adrenal tumours in Spain: report of a case and review of the five previously published patients].
  • We report the clinical and hormonal study of a case, a 49 years old male, since his first consultation until his death 6 years after the initial diagnosis, and a review of the other 5 Spanish patients previously published.
  • His initial symptoms were gynecomastia and libido decrease, with increase of plasmatic and urinary oestrogen levels, plasma testosterone near low normal level and a right adrenal gland tumour that, after its removal, showed a benign histology and was classified as an adrenocortical adenoma.
  • The main special feature of this case is the apparently benign initial adrenal tumour with only oestrogen hypersecretion, and its relapse 3 years later with secretion of several steroid hormones, generalized metastasis and no response to medical therapy.
  • [MeSH-major] Adenoma / complications. Adrenal Gland Neoplasms / complications. Feminization / etiology
  • [MeSH-minor] Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local / complications. Spain

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20096213.001).
  • [ISSN] 1575-0922
  • [Journal-full-title] Endocrinología y nutrición : órgano de la Sociedad Española de Endocrinología y Nutrición
  • [ISO-abbreviation] Endocrinol Nutr
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 12
  •  go-up   go-down


57. Nosho K, Yamamoto H, Takamaru H, Hamamoto Y, Goto A, Yoshida Y, Arimura Y, Endo T, Hirata K, Imai K: A case of colorectal carcinoma in adenoma analyzed by a cDNA array. Int J Colorectal Dis; 2005 May;20(3):287-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of colorectal carcinoma in adenoma analyzed by a cDNA array.
  • Colonoscopy showed a Is-type tumor of 45 mm in diameter in the cecum and three Is-type tumors in the ascending colon.
  • Microscopically, the large tumor consisted of a well-differentiated adenocarcinoma with a tubulovillous adenoma (TVA) component (carcinoma in adenoma).
  • All of the four tumor tissues were classified as microsatellite stable (MSS) according to the National Cancer Institute guideline for analysis of microsatellite instability (MSI).
  • K-ras mutation was detected in both CA and TVA lesions of the carcinoma in adenoma.
  • To clarify relevant alterations of gene expression associated with adenoma-carcinoma progression, the gene expression profiles of these tumor tissues were analyzed by a cDNA array.
  • The results were further substantiated by comparison of the gene expression profiles of CA and TVA lesions of the carcinoma in adenoma.
  • CONCLUSION: The results suggest that overexpression of IGF-II played an important role in the progression of adenoma to carcinoma in this patient.
  • [MeSH-major] Adenocarcinoma / genetics. Adenoma, Villous / genetics. Colorectal Neoplasms / genetics. DNA, Complementary / analysis. Neoplasms, Multiple Primary
  • [MeSH-minor] Aged. Biomarkers, Tumor / genetics. Colonoscopy. Diagnosis, Differential. Female. Follow-Up Studies. Gene Expression Regulation, Neoplastic / physiology. Genes, ras / genetics. Humans. Immunohistochemistry. Insulin-Like Growth Factor II / genetics. Mutation. Pedigree. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 1990 Sep 15;46(3):405-10 [1975564.001]
  • [Cites] Endoscopy. 2001 Apr;33(4):367-73 [11315901.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] Gut. 1999 May;44(5):704-8 [10205209.001]
  • [Cites] Br J Cancer. 1997;76(1):60-6 [9218734.001]
  • [Cites] Oncogene. 2002 Jun 13;21(26):4120-8 [12037668.001]
  • [Cites] Oncology. 2000 Sep;59(3):210-6 [11053988.001]
  • [Cites] Cancer Res. 1986 Dec;46(12 Pt 1):6169-73 [3779638.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] J Gastroenterol. 2002 Nov;37 Suppl 14:83-6 [12572872.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3124-30 [11306497.001]
  • (PMID = 15490195.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Complementary; 0 / RNA, Messenger; 67763-97-7 / Insulin-Like Growth Factor II
  •  go-up   go-down


58. Iwai Y, Yamanaka K, Yoshioka K, Yoshimura M, Honda Y, Matsusaka Y, Komiyama M, Yasui T: [The usefulness of adjuvant therapy using gamma knife radiosurgery for the recurrent or residual nonfunctioning pituitary adenomas]. No Shinkei Geka; 2005 Aug;33(8):777-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The usefulness of adjuvant therapy using gamma knife radiosurgery for the recurrent or residual nonfunctioning pituitary adenomas].
  • We evaluated the treatment results of nonfunctioning pituitary adenomas in the era of radiosurgery.
  • Between January 1994 and December 2003, we operated on 44 patients with nonfunctioning pituitary adenomas.
  • Gamma knife radiosurgery was performed for residual tumor in 26 patients and for recurrence in 2 patients.
  • The mean tumor diameter at the gamma knife radiosurgery was 18.2 mm (7.9 to 26.3 mm).
  • The treatment dose was a mean of 12.3 Gy (8 to 16 Gy) to the tumor margin.
  • Tumor growth control was able to be achieved in 26 patients (93%).
  • Surgical resection using transsphenoidal surgery and subsequent gamma knife radiosurgery for residual and recurrent tumor proved to have a highly effective tumor growth control rate, and maintained the quality of life in patients with nonfunctioning pituitary adenomas.
  • [MeSH-major] Adenoma / surgery. Neoplasm Recurrence, Local / surgery. Neoplasm, Residual / surgery. Pituitary Neoplasms / surgery. Radiosurgery

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16095207.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


59. Zermani R, Chelbi E, Farah F, Rameh S, Kourda N, Ferchichi L, Sayari S, Zaouche A, Ben Jilani S: [Serrated adenoma of the appendix associated with colonic adenocarcinoma]. Tunis Med; 2009 Jan;87(1):97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Serrated adenoma of the appendix associated with colonic adenocarcinoma].
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma / pathology. Appendiceal Neoplasms / pathology. Colonic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19522437.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Tunisia
  •  go-up   go-down


60. Gingalewski CA, Newman KD: Seminars: controversies in the management of pediatric thyroid malignancy. J Surg Oncol; 2006 Dec 15;94(8):748-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It often presents at advanced stages, yet behaves in a benign manner, when compared to its adult counterpart.
  • The best operative and adjuvant strategy for these children can only be determined when a better understanding of the tumor cell biology and genetics of this cancer is known.
  • [MeSH-minor] Adenoma / genetics. Adult. Carcinoma, Papillary. Carcinoma, Papillary, Follicular / secondary. Carcinoma, Papillary, Follicular / surgery. Child. Combined Modality Therapy. Disease-Free Survival. Humans. Hypoparathyroidism / etiology. Lymph Node Excision. Monitoring, Intraoperative. Mutation. Parathyroid Hormone / blood. Postoperative Complications. Proto-Oncogene Proteins c-ret / genetics. Recurrent Laryngeal Nerve Injuries. Retrospective Studies

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17131405.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / Parathyroid Hormone; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret
  • [Number-of-references] 15
  •  go-up   go-down


61. Giovanella L, Suriano S, Maffioli M, Ceriani L, Spriano G: (99m)Tc-sestamibi scanning in thyroid nodules with nondiagnostic cytology. Head Neck; 2010 May;32(5):607-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eight patients with a final histologic diagnosis of benign lesions (3 with follicular adenomas) also had MIBI-positive scans.
  • Histology is still necessary to distinguish benign from malignant disease in a MIBI-positive nodule but unnecessary surgery could have been reduced from 71 to 8 cases in our series.
  • [MeSH-minor] Adenoma / radionuclide imaging. Biopsy, Fine-Needle. Carcinoma, Papillary / radionuclide imaging. Carcinoma, Papillary, Follicular / radionuclide imaging. Humans. Predictive Value of Tests. Prospective Studies. Sensitivity and Specificity. Thyroid Diseases / radionuclide imaging. Thyroid Gland / pathology. Ultrasonography, Interventional

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19693945.001).
  • [ISSN] 1097-0347
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


62. Endo F, Shiga Y, Minagawa S, Iwabuchi T, Fujisaki A, Yashi M, Hattori K, Muraishi O: Anteroposterior dissection HoLEP: a modification to prevent transient stress urinary incontinence. Urology; 2010 Dec;76(6):1451-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Sixty-eight consecutive patients with benign prostatic hyperplasia underwent HoLEP from January to December 2008.
  • The next 37 cases (Surgery 2) underwent anteroposterior dissection HoLEP, where adenoma was dissected antegradely.
  • This antegrade movement of the cystoscope allows the apical gland to be removed from the sphincter without causing damage.
  • [MeSH-major] Adenoma / surgery. Laser Therapy / methods. Lasers, Solid-State / therapeutic use. Postoperative Complications / prevention & control. Prostatic Hyperplasia / surgery. Prostatic Neoplasms / surgery. Urinary Incontinence, Stress / prevention & control


63. Tagliati F, Gentilin E, Buratto M, Molè D, degli Uberti EC, Zatelli MC: Magmas, a gene newly identified as overexpressed in human and mouse ACTH-secreting pituitary adenomas, protects pituitary cells from apoptotic stimuli. Endocrinology; 2010 Oct;151(10):4635-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magmas, a gene newly identified as overexpressed in human and mouse ACTH-secreting pituitary adenomas, protects pituitary cells from apoptotic stimuli.
  • Pituitary tumors are mostly benign, being locally invasive in 5-35% of cases.
  • We here report the identification of a cDNA, corresponding to Magmas gene (mitochondria-associated protein involved in granulocyte-macrophage colony-stimulating factor signal transduction), which is highly expressed in two different ACTH-secreting mouse pituitary adenoma cell lines as compared with normal pituitary as well as in two thirds of 64 examined pituitary adenomas as compared with human normal pituitary.
  • Tim 16, the mitochondrial protein encoded by Magmas, was indeed expressed in a mouse ACTH-secreting pituitary adenoma cell line, AtT-20 D16v-F2 cells, in a subcellular compartment likely corresponding to mitochondria.
  • Our data demonstrate that Magmas is overexpressed in mouse and human ACTH-secreting pituitary adenomas.
  • [MeSH-major] ACTH-Secreting Pituitary Adenoma / genetics. Adenoma / genetics. Apoptosis / genetics. Mitochondrial Proteins / physiology
  • [MeSH-minor] Animals. Cell Proliferation. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / pathology. Cells, Cultured. Cytoprotection / drug effects. Cytoprotection / genetics. Gene Expression Regulation, Neoplastic / drug effects. Humans. Mice. Pituitary Gland / metabolism. RNA, Small Interfering / pharmacology. Up-Regulation / drug effects


64. Vinikoor LC, Robertson DJ, Baron JA, Silverman WB, Sandler RS: Cholecystectomy and the risk of recurrent colorectal adenomas. Cancer Epidemiol Biomarkers Prev; 2007 Jul;16(7):1523-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cholecystectomy and the risk of recurrent colorectal adenomas.
  • Prior studies have shown an increased risk of colorectal cancer following cholecystectomy, but few studies have explored the association between cholecystectomy and the risk of colorectal adenomas.
  • We used data from three large randomized adenoma chemoprevention trials to explore the association between cholecystectomy and the occurrence of adenomas.
  • After adjusting for confounding factors, we found no increased risk for adenomas among individuals who had undergone cholecystectomy [risk ratio (RR), 1.02; 95% confidence interval (95% CI), 0.88-1.18].
  • There was a slight increase in the risk of advanced recurrent adenomas (RR, 1.28; 95% CI, 0.94-1.76) and multiple advanced recurrent adenomas (RR, 1.34; 95% CI, 0.97-1.85) but the 95% CIs included the null in both cases.
  • We conclude that the increased risk for colorectal cancer following cholecystectomy seems to be due to a biological process occurring after the adenoma has developed.
  • [MeSH-major] Adenoma / etiology. Cholecystectomy / adverse effects. Colorectal Neoplasms / etiology. Neoplasm Recurrence, Local / etiology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17627020.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / P30 DK34987; United States / NIDDK NIH HHS / DK / R01 DK44684; United States / NIDDK NIH HHS / DK / T32 DK07634
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


65. Petramala L, Battisti P, Lauri G, Palleschi L, Cotesta D, Iorio M, De Toma G, Sciomer S, Letizia C: Cushing's syndrome patient who exhibited congestive heart failure. J Endocrinol Invest; 2007 Jun;30(6):525-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this article we report the case of a 28-yr-old woman with CS secondary to adrenal adenoma who exhibited congestive heart failure as an initial symptom.
  • A laparoscopic right adrenalectomy was performed and pathological examination of the gland showed a benign adrenocortical adenoma.
  • In conclusion we report the case of heart failure as the main clinical symptom in CS secondary to adrenal adenoma.
  • [MeSH-major] Adrenocortical Adenoma / complications. Cushing Syndrome. Heart Failure / etiology


66. Kaminski MF, Regula J, Kraszewska E, Polkowski M, Wojciechowska U, Didkowska J, Zwierko M, Rupinski M, Nowacki MP, Butruk E: Quality indicators for colonoscopy and the risk of interval cancer. N Engl J Med; 2010 May 13;362(19):1795-803
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Although rates of detection of adenomatous lesions (tumors or polyps) and cecal intubation are recommended for use as quality indicators for screening colonoscopy, these measurements have not been validated, and their importance remains uncertain.
  • The endoscopist's rate of detection of adenomas was significantly associated with the risk of interval colorectal cancer (P=0.008), whereas the rate of cecal intubation was not significantly associated with this risk (P=0.50).
  • The hazard ratios for adenoma detection rates of less than 11.0%, 11.0 to 14.9%, and 15.0 to 19.9%, as compared with a rate of 20.0% or higher, were 10.94 (95% confidence interval [CI], 1.37 to 87.01), 10.75 (95% CI, 1.36 to 85.06), and 12.50 (95% CI, 1.51 to 103.43), respectively (P=0.02 for all comparisons).
  • CONCLUSIONS: The adenoma detection rate is an independent predictor of the risk of interval colorectal cancer after screening colonoscopy.
  • [MeSH-major] Adenoma / diagnosis. Clinical Competence. Colonic Polyps / diagnosis. Colonoscopy / standards. Colorectal Neoplasms / diagnosis. Quality Indicators, Health Care


67. Steinmetz J, Spyckerelle Y, Guéguen R, Dupré C: Colorectal cancer screening in Health Examination Centers. Gastroenterol Clin Biol; 2006 Jun-Jul;30(6-7):832-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A colonic exploration was performed in 69% of high-risk subjects and enabled detection of cancer in 85 and adenomas in 1683.
  • A colonic exploration was performed in 88% of subjects with a positive fecal occult blood test and enabled detection of 674 cancers (positive predictive value of fecal occult blood test (PPV)=4.7%) including 174 Dukes A, and 2618 adenomas (PPV=18%) including 776 adenomas measuring more than 10 mm (PPV=5.4%).
  • [MeSH-major] Adenoma / diagnosis. Colorectal Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16885866.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] France
  •  go-up   go-down


68. Bampton PA, Sandford JJ, Cole SR, Smith A, Morcom J, Cadd B, Young GP: Interval faecal occult blood testing in a colonoscopy based screening programme detects additional pathology. Gut; 2005 Jun;54(6):803-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: The main aim of this study was to determine whether a one-off interval faecal occult blood test (FOBT) facilitates the detection of significant neoplasia within a colonoscopic based surveillance programme.
  • Secondary aims were to determine if invitees were interested in participating in interval screening, and to determine whether interval lesions were missed or whether they developed rapidly since the previous colonoscopy PATIENTS: Patients enrolled in a colonoscopic based screening programme due to a personal history of colorectal neoplasia or a significant family history.
  • A positive result was followed by colonoscopy; significant neoplasia was defined as colorectal cancer, adenomas either > or =10 mm or with a villous component, high grade dysplasia, or multiplicity (>/=3 adenomas).
  • These consisted of six colorectal cancers and eight significant adenomas.
  • CONCLUSIONS: A one off immunochemical faecal occult blood test within a colonoscopy based surveillance programme had a participation rate of nearly 50% and appeared to detect additional pathology, especially in patients with a past history of colonic neoplasia.

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med J Aust. 2002 Feb 18;176(4):155-7 [11913914.001]
  • [Cites] J Med Screen. 2002;9(4):147-52 [12518003.001]
  • [Cites] Colorectal Dis. 2003 Jan;5(1):45-8 [12780926.001]
  • [Cites] J Med Screen. 2003;10(3):123-8 [14561263.001]
  • [Cites] Gastroenterology. 1987 Nov;93(5):1009-13 [3653628.001]
  • [Cites] Am J Gastroenterol. 1999 Jan;94(1):194-9 [9934755.001]
  • [Cites] N Engl J Med. 1993 May 13;328(19):1365-71 [8474513.001]
  • [Cites] Aust N Z J Surg. 1994 Jul;64(7):464-9 [8010915.001]
  • [Cites] N Engl J Med. 1996 Jan 18;334(3):155-9 [8531970.001]
  • [Cites] Gastroenterology. 1997 Feb;112(2):594-642 [9024315.001]
  • [Cites] N Engl J Med. 1993 Apr 1;328(13):901-6 [8446136.001]
  • (PMID = 15888788.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1774549
  •  go-up   go-down


69. Yang QX, Shao CK, Feng ZY, Huang BQ, Han AJ, Xiong M, Zhao WL, Wu TT: [Detection of cytokeratin 19 and thyroperoxidase expressions in the diagnosis of thyroid diseases]. Di Yi Jun Yi Da Xue Xue Bao; 2005 Jun;25(6):678-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the value of detecting cytokeratin 19(CK19) and thyroperoxidase (TPO) expression in the diagnosis of thyroid diseases including thyroid carcinoma, multinodular goiter, adenoma and Hashimoto thyroiditis.
  • METHODS: SP immunohistochemistry was used to detect the expressions of CK19 and TPO in paraffin-embedded thyroid tissue specimens obtained from 62 patients with thyroid carcinoma (30 with papillary carcinomas, 22 with follicular variant of papillary carcinomas, and 10 with follicular carcinomas) and 44 with benign thyroid diseases (including 22 with multinodular goiters, 14 with adenoma, and 8 with Hashimoto thyroiditis).
  • RESULTS: CK19 expression was detected in 96.8% of the thyroid carcinomas and in 4.5% of benign thyroid diseases, demonstrating a significant difference in CK19 expression between the two thyroid diseases (P<0.01).
  • TPO expression was found in 100% of benign thyroid disease and in 3.2% of thyroid carcinoma, showing also a significant difference between them (P<0.01).
  • [MeSH-major] Biomarkers, Tumor. Iodide Peroxidase / analysis. Keratin-19 / analysis. Thyroid Diseases / diagnosis. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / metabolism. Adult. Aged. Aged, 80 and over. Carcinoma, Papillary, Follicular / diagnosis. Carcinoma, Papillary, Follicular / metabolism. Female. Goiter, Nodular / diagnosis. Goiter, Nodular / metabolism. Hashimoto Disease / diagnosis. Hashimoto Disease / metabolism. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15958307.001).
  • [ISSN] 1000-2588
  • [Journal-full-title] Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA
  • [ISO-abbreviation] Di Yi Jun Yi Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-19; EC 1.11.1.8 / Iodide Peroxidase
  •  go-up   go-down


70. Cherebillo VIu, Gofman VR, Polezhaev AV: [Transsphenoidal surgery for large and giant pituitary adenomas by intraoperative video endomonitoring]. Zh Vopr Neirokhir Im N N Burdenko; 2005 Jan-Mar;(1):12-5; discussion 15-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transsphenoidal surgery for large and giant pituitary adenomas by intraoperative video endomonitoring].
  • The paper analyzes the outcomes of surgical treatment of patients with pituitary adenomas on the basis of 614 performed transsphenoidal surgical appliances, of which there were 209 large and giant pituitary adenomas.
  • The use of intraoperative video endomonitoring during these interventions could substantially reduced the number of complications, enhance the radicalism and selectivity of a surgical appliance.
  • By using such advantages as endoscopy as powerful lighting, an endomicroscopic phenomenon, and a lateral view, at surgery we could precisely determine the borders of an adenoma, the site and sizes of non-removed tumors fragments.
  • The lateral view of an endoscope permits removal of a tumor via the optimal access, prevention of traumatization of cerebral structures and the contents of cavernous sinuses.
  • Thus, the accumulated experience allows the authors to recommend using intraoperative video endomonitoring during transsphenoidal surgery for pituitary adenomas.
  • [MeSH-major] Adenoma / surgery. Neuroendoscopy. Pituitary Neoplasms / surgery. Sphenoid Sinus / surgery. Video-Assisted Surgery

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15912863.001).
  • [ISSN] 0042-8817
  • [Journal-full-title] Zhurnal voprosy neĭrokhirurgii imeni N. N. Burdenko
  • [ISO-abbreviation] Zh Vopr Neirokhir Im N N Burdenko
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


71. Harris DL, Washington MK, Hood DB, Roberts LJ 2nd, Ramesh A: Dietary fat-influenced development of colon neoplasia in Apc Min mice exposed to benzo(a)pyrene. Toxicol Pathol; 2009 Dec;37(7):938-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dietary fat-influenced development of colon neoplasia in Apc Min mice exposed to benzo(a)pyrene.
  • An increased prevalence of adenomas in colons of mice that ingested B(a)P through saturated dietary fat compared to unsaturated fat and controls (p < .05) was noticed.
  • Interestingly, we also observed adenomas with high-grade dysplasia in the B(a)P + saturated fat group, and these incidences were frequent at the 100 microg/kg B(a)P dose.
  • On the other hand, the B(a)P-alone and unsaturated-fat groups did not show significant differences in the numbers of adenomas and invasive tumors in the both jejunum and the colon.

  • MedlinePlus Health Information. consumer health - Dietary Fats.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Benzo(a)pyrene .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Prog Lipid Res. 1999 May;38(3):261-71 [10664796.001]
  • [Cites] J Lipid Res. 1985 Apr;26(4):428-34 [4009061.001]
  • [Cites] J Agric Food Chem. 2001 May;49(5):2493-6 [11368625.001]
  • [Cites] Dig Dis Sci. 2001 Jul;46(7):1367-80 [11478486.001]
  • [Cites] Carcinogenesis. 2002 Jul;23(7):1131-7 [12117770.001]
  • [Cites] Chemosphere. 2002 Sep;48(8):843-8 [12222778.001]
  • [Cites] Carcinogenesis. 2002 Nov;23(11):1839-49 [12419832.001]
  • [Cites] J Biochem Mol Biol. 2003 Jan 31;36(1):35-42 [12542973.001]
  • [Cites] Gastroenterology. 2003 Mar;124(3):762-77 [12612914.001]
  • [Cites] Nutr Rev. 2003 Jul;61(7):255-8 [12918879.001]
  • [Cites] Reprod Nutr Dev. 2003 Mar-Apr;43(2):145-54 [12956314.001]
  • [Cites] Exp Toxicol Pathol. 2003 Sep;55(2-3):91-106 [14620530.001]
  • [Cites] Free Radic Res. 2003 Sep;37(9):947-56 [14670002.001]
  • [Cites] Int J Cancer. 1990 Oct 15;46(4):640-7 [2210884.001]
  • [Cites] Mutat Res. 1991 Mar-Apr;259(3-4):251-61 [2017211.001]
  • [Cites] Cell. 1991 Aug 9;66(3):601-13 [1678319.001]
  • [Cites] Toxicol Ind Health. 1991 May;7(3):141-57 [1949056.001]
  • [Cites] J Cell Biol. 1992 Mar;116(6):1517-26 [1541640.001]
  • [Cites] Science. 1992 May 1;256(5057):668-70 [1350108.001]
  • [Cites] Lipids. 1992 Oct;27(10):807-13 [1435100.001]
  • [Cites] Environ Health Perspect. 1993 Oct;101 Suppl 3:37-42 [8143643.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] Carcinogenesis. 1997 Apr;18(4):721-30 [9111206.001]
  • [Cites] Carcinogenesis. 1999 Jun;20(6):1097-101 [10357794.001]
  • [Cites] Semin Cancer Biol. 1999 Aug;9(4):245-54 [10448112.001]
  • [Cites] J Cell Biochem. 2004 Dec 15;93(6):1242-54 [15486983.001]
  • [Cites] Recent Results Cancer Res. 2005;166:177-211 [15648191.001]
  • [Cites] Science. 2005 Mar 25;307(5717):1904-9 [15790842.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1626-32 [16030093.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):2030-4 [16103456.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):8034-41 [16140978.001]
  • [Cites] Cancer Lett. 2006 Aug 28;240(2):268-78 [16288829.001]
  • [Cites] Carcinogenesis. 2006 Oct;27(10):2038-46 [16675473.001]
  • [Cites] Curr Opin Gastroenterol. 2007 Jan;23(1):48-54 [17133085.001]
  • [Cites] J Nutr Biochem. 2007 Apr;18(4):236-49 [16781860.001]
  • [Cites] Genes Dev. 2007 Oct 15;21(20):2525-38 [17938238.001]
  • [Cites] Cancer Res. 2007 Oct 15;67(20):9937-44 [17942926.001]
  • [Cites] Int J Environ Res Public Health. 2008 Mar;5(1):41-8 [18441404.001]
  • [Cites] Pathol Res Pract. 2008;204(7):479-90 [18538487.001]
  • [Cites] Cancer Res. 2008 Sep 15;68(18):7394-402 [18794127.001]
  • [Cites] Planta Med. 2008 Oct;74(13):1602-7 [18604780.001]
  • [Cites] Carcinogenesis. 2009 Feb;30(2):183-96 [19037092.001]
  • [Cites] Oncogene. 1999 Sep 20;18(38):5325-33 [10498885.001]
  • [Cites] J Food Prot. 2003 Dec;66(12):2325-31 [14672232.001]
  • [Cites] J Nutr. 2004 Apr;134(4):776-84 [15051825.001]
  • [Cites] Environ Mol Mutagen. 2004;44(1):44-55 [15199546.001]
  • [Cites] Int J Toxicol. 2004;23(5):301-33 [15513831.001]
  • [Cites] J Lipid Res. 1984 Dec 1;25(12):1337-42 [6530591.001]
  • [Cites] Curr Opin Oncol. 2001 Jan;13(1):63-9 [11148689.001]
  • (PMID = 19841130.001).
  • [ISSN] 1533-1601
  • [Journal-full-title] Toxicologic pathology
  • [ISO-abbreviation] Toxicol Pathol
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / F31 ES017391-01; United States / NCI NIH HHS / CA / R03 CA130112; United States / NIEHS NIH HHS / ES / F31 ES017391; United States / NIEHS NIH HHS / ES / 1S11ES014156-01A1; United States / NHLBI NIH HHS / HL / T32 HL007735-12; United States / NIEHS NIH HHS / ES / S11 ES014156; United States / NCI NIH HHS / CA / R03 CA130112-01; United States / NCI NIH HHS / CA / R01 CA142845; United States / NCI NIH HHS / CA / 1R03CA130112-01; United States / NHLBI NIH HHS / HL / 5T32HL007735-12; United States / NHLBI NIH HHS / HL / T32 HL007735; United States / NIEHS NIH HHS / ES / S11 ES014156-01A1; United States / NIEHS NIH HHS / ES / 1F31ES017391-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Dietary Fats; 3417WMA06D / Benzo(a)pyrene
  • [Other-IDs] NLM/ NIHMS248414; NLM/ PMC2982189
  •  go-up   go-down


72. Onofri C, Losa M, Uhl E, Stalla GK, Renner U: Immunohistochemical analysis of VEGF-C/VEGFR-3 system and lymphatic vessel extent in normal and adenomatous human pituitary tissues. Exp Clin Endocrinol Diabetes; 2008 Mar;116(3):152-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical analysis of VEGF-C/VEGFR-3 system and lymphatic vessel extent in normal and adenomatous human pituitary tissues.
  • We assessed the expression of VEGF-C and VEGFR-3, together with blood and lymphatic vessel extents and proliferation index (PI) values, by immunohistochemistry (IHC) in 6 normal human pituitary glands and 53 pituitary adenomas of different tumour grade, on consecutive tissue sections.
  • VEGF-C was detected in around 10% of the endocrine cells in normal pituitary tissue, while this gland was devoid of lymphatic vascularization and showed very few vessels positive for VEGFR-3.
  • Concerning tumour tissue, most of the adenomas showing VEGF-C immunoreactivity (21/47) were positive in 60% of the tumour cells and the ones positive for VEGFR-3 showed a number of immunostained vessels higher than those observed in the normal pituitary.
  • In conclusion, the VEGF-C/VEGFR-3 system might be involved in controlling tumour angiogenesis in the pituitary adenomas lacking lymphatic vessels, but may also play a role in starting the process of tumour lymphangiogenesis.
  • [MeSH-major] Adenoma / metabolism. Lymphatic Vessels / metabolism. Pituitary Neoplasms / metabolism. Vascular Endothelial Growth Factor C / metabolism. Vascular Endothelial Growth Factor Receptor-2 / metabolism

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18205092.001).
  • [ISSN] 0947-7349
  • [Journal-full-title] Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
  • [ISO-abbreviation] Exp. Clin. Endocrinol. Diabetes
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor C; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


73. Gruschwitz T, Breza J, Wunderlich H, Junker K: Improvement of histopathological classification of adrenal gland tumors by genetic differentiation. World J Urol; 2010 Jun;28(3):329-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improvement of histopathological classification of adrenal gland tumors by genetic differentiation.
  • PURPOSE: There are often problems in differentiating between benign and malignant adrenal gland tumors by imaging and histopathology.
  • On account of considerable differences in the therapy and aftercare of benign and malignant adrenal tumors, correct classification of tumor type is of greatest importance.
  • The purpose of this study was to define specific genetic alterations differentiating between adenomas and carcinomas.
  • METHODS: DNA was isolated from tumor areas in paraffin sections and amplified by a modified protocol for DOP-PCR.
  • After labeling of tumor-DNA and normal DNA with biotin-dUTP and digoxigenin-dUTP, respectively, comparative genomic hybridization (CGH) was carried out according to standard protocols.
  • Retrospectively, 26 (16 adenomas and 10 carcinomas) tumors of the adrenal cortex were analyzed.
  • RESULTS: Genetic alterations were found in 5/16 adenomas (31.25%) and in all adrenocortical carcinomas.
  • The mean number of genetic changes per tumor was 8.7 (range 6-12) in carcinomas.
  • The benign cortical tumors present 1.6 changes (range 0-3) per tumor.
  • Only a moderate correlation between number of alterations and size of tumor was seen.
  • CONCLUSIONS: Genetic evaluation facilitates differentiation between adrenal gland tumors.
  • [MeSH-major] Adenoma / classification. Adenoma / genetics. Adrenal Cortex Neoplasms / classification. Adrenal Cortex Neoplasms / genetics. Carcinoma / genetics
  • [MeSH-minor] Adrenalectomy / methods. Adult. Aged. Biomarkers, Tumor / analysis. Biopsy, Fine-Needle. Chromosome Aberrations. Chromosome Mapping. Cohort Studies. DNA, Neoplasm / analysis. Female. Humans. Immunohistochemistry. Male. Middle Aged. Polymerase Chain Reaction. Retrospective Studies. Sensitivity and Specificity. Statistics, Nonparametric. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genomics. 1992 Jul;13(3):718-25 [1639399.001]
  • [Cites] Am J Pathol. 1999 Oct;155(4):1039-45 [10514385.001]
  • [Cites] NIH Consens State Sci Statements. 2002 Feb 4-6;19(2):1-25 [14768652.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Mar;88(3):998-1001 [12629075.001]
  • [Cites] Surg Gynecol Obstet. 1993 Apr;176(4):307-9 [8460403.001]
  • [Cites] Eur J Surg Oncol. 2003 Oct;29(8):689-92 [14511619.001]
  • [Cites] World J Surg. 2001 Jul;25(7):914-26 [11572033.001]
  • [Cites] Am J Clin Pathol. 1979 Sep;72(3):390-9 [474519.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Jun;28(2):145-52 [10824999.001]
  • [Cites] J Urol. 2003 Jan;169(1):5-11 [12478091.001]
  • [Cites] Am J Surg Pathol. 1989 Mar;13(3):202-6 [2919718.001]
  • [Cites] Endocr Rev. 1995 Aug;16(4):460-84 [8521790.001]
  • [Cites] Cancer Res. 1996 Sep 15;56(18):4219-23 [8797595.001]
  • [Cites] Eur J Endocrinol. 2003 Oct;149(4):273-85 [14514341.001]
  • [Cites] Eur J Clin Invest. 2000 Dec;30 Suppl 3:58-62 [11281370.001]
  • [Cites] Radiol Clin North Am. 2008 Jan;46(1):65-78, vi [18328880.001]
  • [Cites] World J Surg. 2001 Jul;25(7):948-56 [11572037.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):941-50 [11844815.001]
  • [Cites] Endocr Rev. 2004 Apr;25(2):309-40 [15082524.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jul;87(7):3467-74 [12107267.001]
  • [Cites] Cancer. 1985 Feb 15;55(4):766-73 [3967172.001]
  • [Cites] Am J Surg Pathol. 1984 Mar;8(3):163-9 [6703192.001]
  • (PMID = 20364258.001).
  • [ISSN] 1433-8726
  • [Journal-full-title] World journal of urology
  • [ISO-abbreviation] World J Urol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  •  go-up   go-down


74. Mahe E, El-Shinnawy I: A "tumour trifecta:" myelolipomata arising within an adrenocortical adenoma ipsilateral to a synchronous clear cell renal cell carcinoma. Malays J Pathol; 2010 Dec;32(2):123-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A "tumour trifecta:" myelolipomata arising within an adrenocortical adenoma ipsilateral to a synchronous clear cell renal cell carcinoma.
  • We present an intriguing case of adrenal myelolipomata occurring within an adrenocortical adenoma in concert with an ipsilateral clear cell renal cell carcinoma.
  • The adrenal mass was a cortical adenoma with solid and nested patterns, with discrete zones consisting of erythroid, myeloid and megakaryocytic cells intermixed with mature adipocytes.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenocortical Adenoma / pathology. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology. Myelolipoma / pathology. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Middle Aged


75. Anaforoğlu I, Siviloğlu C, Livaoğlu A, Algün E: Granulomatous infiltration of a parathyroid adenoma presenting as primary hyperparathyroidism in a woman: a case report. J Med Case Rep; 2010;4:400
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulomatous infiltration of a parathyroid adenoma presenting as primary hyperparathyroidism in a woman: a case report.
  • Although most patients with granulomatous disease-related hypercalcemia are asymptomatic, symptoms and signs of chronic hypercalcemia can occur.
  • There are many reports about co-presentation of a parathyroid adenoma and a granulomatous disorder in the literature.
  • However, granulomatous inflammation within a parathyroid adenoma is very rare.
  • She underwent excision of an enlarged right inferior parathyroid gland.
  • Histopathological analysis revealed features of a parathyroid adenoma with foci of epithelioid non-caseating granulomas.
  • She is still normocalcemic at the ninth month after surgery and is being followed for the possible manifestation of an occult disease.
  • CONCLUSION: Granulomatous infiltration of a parathyroid adenoma is a rare condition.
  • Pathological examination of the excised adenoma is the only way to diagnose the underlying occult granulomatous disorder.
  • Clinicians should also consider persistent hypercalcemia to be a possible indicator of concomitant parathyroid adenoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Pathol. 2001 Fall;12(3):355-9 [11740057.001]
  • [Cites] Endocr Pathol. 2005 Summer;16(2):157-60 [16199902.001]
  • [Cites] Arch Intern Med. 1980 Nov;140(11):1547-8 [7436654.001]
  • [Cites] Arch Otorhinolaryngol. 1987;243(6):392-4 [3566623.001]
  • [Cites] J Nephrol. 2008 May-Jun;21(3):438-41 [18587734.001]
  • (PMID = 21143903.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3019160
  •  go-up   go-down


76. Makino K, Kojima R, Nakamura H, Morioka M, Iyama K, Shigematsu K, Kuratsu J: Ectopic adrenal cortical adenoma in the spinal region: case report and review of the literature. Brain Tumor Pathol; 2010 Oct;27(2):121-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ectopic adrenal cortical adenoma in the spinal region: case report and review of the literature.
  • Immunohistochemically, the tumor cells were strongly positive for inhibin-alpha, positive for synaptophysin and vimentin, and negative for GFAP, EMA, S-100, NSA, and chromogranin A.
  • This case confirms the occurrence of adrenocortical adenoma in the CNS.
  • We suggest that this tumor should be considered in the differential diagnosis of CNS tumors.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenocortical Adenoma / pathology. Spinal Cord Neoplasms / pathology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21046315.001).
  • [ISSN] 1861-387X
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Steroidogenic Factor 1; 0 / inhibin-alpha subunit; 57285-09-3 / Inhibins
  •  go-up   go-down


77. Cavallo LM, Prevedello D, Esposito F, Laws ER Jr, Dusick JR, Messina A, Jane JA Jr, Kelly DF, Cappabianca P: The role of the endoscope in the transsphenoidal management of cystic lesions of the sellar region. Neurosurg Rev; 2008 Jan;31(1):55-64; discussion 64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cystic mass lesions within the sella turcica are common, and they include cystic pituitary adenomas, craniopharyngiomas, Rathke's cleft cysts, arachnoid cysts, and other entities.
  • The series consisted of 26 pituitary macroadenomas, 20 Rathke's cleft cysts, 18 craniopharyngiomas, 10 arachnoid cysts, one craniopharyngioma associated with an adrenocorticotropic hormone-secreting adenoma, and one chordoid glioma.
  • Endoscopic exploration of the sellar cavity during transsphenoidal surgery offers both general and specific advantages in the treatment of a variety of different cystic sellar lesions.
  • Its routine use during transsphenoidal surgery for such lesions is recommended to achieve maximal and safe tumor removal.
  • [MeSH-minor] Adenoma / surgery. Adult. Aged. Arachnoid Cysts / surgery. Central Nervous System Cysts / surgery. Craniopharyngioma / surgery. Female. Humans. Male. Middle Aged. Neurosurgical Procedures / instrumentation. Neurosurgical Procedures / methods. Pituitary Neoplasms / surgery. Sphenoid Sinus

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Neurol. 1991 Jun;35(6):446-54 [2053058.001]
  • [Cites] Front Horm Res. 2006;34:105-26 [16474218.001]
  • [Cites] Neurosurgery. 2005;56(1):124-8; discussion 129 [15617594.001]
  • [Cites] Neurosurgery. 1998 Jan;42(1):7-16; discussion 16-7 [9442498.001]
  • [Cites] Diagn Cytopathol. 1999 Mar;20(3):137-47 [10086237.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(2):165-9 [10189498.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Nov;84(11):3972-82 [10566636.001]
  • [Cites] Neurosurgery. 2004 Oct;55(4):933-40; discussion 940-1 [15458602.001]
  • [Cites] Childs Nerv Syst. 2005 Aug;21(8-9):696-700 [16041618.001]
  • [Cites] Surg Neurol. 1981 Apr;15(4):274-82 [7245014.001]
  • [Cites] Minim Invasive Neurosurg. 2002 Mar;45(1):47-51 [11932826.001]
  • [Cites] J Neurosurg. 1984 Jan;60(1):8-13 [6689730.001]
  • [Cites] Skull Base. 2003 Feb;13(1):55-58 [15912160.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(4):389-97; discussion 397-8 [10352749.001]
  • [Cites] Childs Nerv Syst. 2004 Nov;20(11-12):863-7 [15185112.001]
  • [Cites] J Neurosurg. 1999 Feb;90(2):237-50 [9950494.001]
  • [Cites] J Neurosurg. 1970 Jul;33(1):48-53 [5427027.001]
  • [Cites] J Neurosurg. 1980 May;52(5):661-6 [7373393.001]
  • [Cites] J Endocrinol Invest. 2004 Nov;27(10):943-8 [15762042.001]
  • [Cites] Pediatr Neurosurg. 1994;21 Suppl 1:57-63 [7841079.001]
  • [Cites] J Neurosurg. 2002 Jul;97(1):3-11 [12134929.001]
  • [Cites] Laryngoscope. 1996 Jul;106(7):914-8 [8667994.001]
  • [Cites] J Neurosurg. 2003 Feb;98(2):350-8 [12593622.001]
  • [Cites] Neurosurgery. 2001 Jul;49(1):94-100; discussion 100-1 [11440465.001]
  • [Cites] AJNR Am J Neuroradiol. 1994 May;15(5):821-7 [8059648.001]
  • [Cites] J Neurosurg. 1977 Sep;47(3):451-8 [894347.001]
  • (PMID = 17922153.001).
  • [ISSN] 0344-5607
  • [Journal-full-title] Neurosurgical review
  • [ISO-abbreviation] Neurosurg Rev
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Germany
  •  go-up   go-down


78. Sathyapalan T, Lowry M, Turnbull LW, Rowland-Hill C, Atkin SL: Mechanism of action of octreotide in acromegalic tumours in vivo using dynamic contrast-enhanced magnetic resonance imaging. Pituitary; 2007;10(3):233-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Amplitude of contrast intake (9.87 +/- 3.52 vs. 4.97 +/- 1.96 P < or = 0.05) and exchange rate (6.27 +/- 1.57 vs. 1.63 +/- 0.76 P value < or = 0.01) were significantly higher at baseline in adenoma compared to normal pituitary tissue but was comparable to normal pituitary tissue after treatment.
  • There was a significant decrease in amplitude of contrast intake and exchange rate which relates to functional vascularity of adenoma at 24 weeks compared to baseline (P-values 0.026 and 0.002 respectively) but there were no significant changes in the normal pituitary tissue.
  • CONCLUSION: DCE-MRI in acromegalic tumours treated with octreotide showed a significant reduction in functional vascularity after octreotide therapy compared to baseline in pituitary adenomas.
  • [MeSH-major] Acromegaly / drug therapy. Adenoma / drug therapy. Angiogenesis Inhibitors / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Growth Hormone-Secreting Pituitary Adenoma / drug therapy. Octreotide / therapeutic use
  • [MeSH-minor] Adult. Aged. Contrast Media. Drug Resistance, Neoplasm. Female. Gadolinium DTPA. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Regional Blood Flow / drug effects. Somatostatin / analogs & derivatives. Somatostatin / therapeutic use

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2005 Mar;90(3):1856-63 [15613435.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Oct;57(4):425-41 [12354124.001]
  • [Cites] Semin Oncol. 1994 Oct;21(5 Suppl 13):61-4 [7992085.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jul;88(7):3105-12 [12843150.001]
  • [Cites] J Comput Assist Tomogr. 1991 Jul-Aug;15(4):621-8 [2061479.001]
  • [Cites] Technol Cancer Res Treat. 2006 Apr;5(2):127-34 [16551132.001]
  • [Cites] Eur J Endocrinol. 2001 Dec;145(6):717-26 [11720896.001]
  • [Cites] Magn Reson Med. 1991 Feb;17(2):357-67 [2062210.001]
  • [Cites] Magn Reson Med. 1992 Mar;24(1):174-6 [1556924.001]
  • [Cites] J Neurosurg. 2002 Sep;97(3):525-30 [12296634.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Mar;85(3):1287-9 [10720077.001]
  • [Cites] Magn Reson Imaging. 1996;14(4):373-80 [8782175.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1580-4 [7878022.001]
  • [Cites] Br J Cancer. 2005 Apr 25;92(8):1493-8 [15812556.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Nov;86(11):5194-200 [11701676.001]
  • [Cites] J Physiol Paris. 2000 May-Aug;94(3-4):205-10 [11087998.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Aug;90(8):4483-8 [15899958.001]
  • [Cites] Pharmacol Ther. 2004 Apr;102(1):61-85 [15056499.001]
  • [Cites] Int J Clin Pharmacol Ther. 2002 Dec;40(12):573-4 [12503819.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Oct;87(10):4554-63 [12364434.001]
  • [Cites] Int J Clin Pharmacol Ther. 2003 Dec;41(12):600-2 [14692711.001]
  • (PMID = 17541750.001).
  • [ISSN] 1386-341X
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents, Hormonal; 0 / Contrast Media; 51110-01-1 / Somatostatin; K2I13DR72L / Gadolinium DTPA; RWM8CCW8GP / Octreotide
  •  go-up   go-down


79. Lieu D: Cytopathologist-performed ultrasound-guided fine-needle aspiration of parathyroid lesions. Diagn Cytopathol; 2010 May;38(5):327-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As most cases are caused by parathyroid adenoma, there is a movement toward preoperative localization of the abnormal gland by ultrasound and/or Tc(99)-sestamibi scan and minimally invasive parathyroidectomy.
  • Three parathyroid adenomas, two benign colloid nodules, one papillary carcinoma, three parathyroid cysts, and one thyroid cyst were diagnosed.
  • The nodules in three patients with parathyroid adenomas were identified as follicular lesion/neoplasm on ICE.
  • Two of these patients had a separate benign colloid nodule and one had a thyroid cyst diagnosed by UG-FNA.
  • The PHPT patient with papillary carcinoma on UG-FNA had the malignancy confirmed at surgery and a sonographically occult parathyroid adenoma.
  • [MeSH-major] Adenoma / pathology. Biopsy, Fine-Needle / methods. Parathyroid Glands / pathology. Parathyroid Glands / ultrasonography. Parathyroid Neoplasms / pathology. Parathyroid Neoplasms / ultrasonography. Thyroid Nodule / pathology. Thyroid Nodule / ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19845029.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Lee SE, Park NH, Park IA, Kang SB, Lee HP: Tubulo-villous adenoma of the vagina. Gynecol Oncol; 2005 Feb;96(2):556-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tubulo-villous adenoma of the vagina.
  • BACKGROUND: Tubulo-villous adenomas are common in the colon and rectum, but extremely rare in the vagina.
  • As far as we know, only two cases of tubulo-villous adenoma have ever been reported.
  • We report the third case of enteric-type tubulo-villous adenoma of the vagina.
  • CASE: A 61-year-old woman presented a symptom of intermittent vaginal spotting and a tumor located outside the vaginal introitus near the urethra.
  • The tumor was excised and pathologically confirmed as a tubulo-villous adenoma.
  • CONCLUSION: Because some tubulo-villous adenomas in the colon and rectum can progress to the cancer, this case requires long-term follow-up to detect recurrence and malignant transformation.
  • [MeSH-major] Adenoma, Villous / pathology. Vaginal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15661252.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 17
  •  go-up   go-down


81. Alzahrani AS, Farhat R, Al-Arifi A, Al-Kahtani N, Kanaan I, Abouzied M: The diagnostic value of fused positron emission tomography/computed tomography in the localization of adrenocorticotropin-secreting pituitary adenoma in Cushing's disease. Pituitary; 2009;12(4):309-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The diagnostic value of fused positron emission tomography/computed tomography in the localization of adrenocorticotropin-secreting pituitary adenoma in Cushing's disease.
  • Despite the high resolution of magnetic resonance imaging (MRI) of the pituitary gland, up to 40% of cases of Cushing's disease (CD) have normal MRI.
  • Objective of this study is to explore the diagnostic potential of PET-CT for localization of adrenocorticotropin-secreting pituitary adenomas in CD.
  • PET-CT was positive in 7 of the 12 cases of CD (58%) showing a focal area of uptake in the pituitary gland.
  • [MeSH-major] ACTH-Secreting Pituitary Adenoma / diagnosis. Pituitary ACTH Hypersecretion / pathology. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging / methods. Male. Middle Aged. Pituitary Gland / metabolism. Pituitary Gland / pathology

  • MedlinePlus Health Information. consumer health - CT Scans.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Nucl Med. 2002 Mar;27(3):176-8 [11852303.001]
  • [Cites] J Clin Endocrinol Metab. 2004 May;89(5):2214-21 [15126544.001]
  • [Cites] N Engl J Med. 1991 Sep 26;325(13):897-905 [1652686.001]
  • [Cites] AJR Am J Roentgenol. 1994 Sep;163(3):680-2 [8079867.001]
  • [Cites] Rinsho Hoshasen. 1990 Mar;35(3):407-10 [2161060.001]
  • [Cites] Clin Endocrinol (Oxf). 2006 Apr;64(4):371-4 [16584507.001]
  • [Cites] Ann Intern Med. 1994 May 15;120(10):817-20 [8154641.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Feb;78(2):418-22 [8106630.001]
  • [Cites] J Nucl Med. 2001 May;42(5 Suppl):1S-93S [11483694.001]
  • [Cites] Lancet. 2006 May 13;367(9522):1605-17 [16698415.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jun;82(6):1780-5 [9177382.001]
  • [Cites] Neurosurgery. 1991 Jun;28(6):826-33 [2067604.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):440-8 [10022398.001]
  • [Cites] J Clin Endocrinol Metab. 2008 May;93(5):1526-40 [18334580.001]
  • [Cites] Clin Endocrinol (Oxf). 1993 Sep;39(3):307-13 [8222293.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 Apr;21(4):690-6 [10782779.001]
  • [Cites] Radiology. 1990 Oct;177(1):39-44 [2399336.001]
  • (PMID = 19387839.001).
  • [ISSN] 1573-7403
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Sandulescu L, Saftoiu A, Dumitrescu D, Ciurea T: Real-time contrast-enhanced and real-time virtual sonography in the assessment of benign liver lesions. J Gastrointestin Liver Dis; 2008 Dec;17(4):475-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Real-time contrast-enhanced and real-time virtual sonography in the assessment of benign liver lesions.
  • The aim of this review is to describe the role of real-time contrast-enhanced and real-time virtual sonography in the assessment of benign liver lesions.
  • [MeSH-minor] Adenoma, Liver Cell / diagnosis. Contrast Media. Focal Nodular Hyperplasia / diagnosis. Hemangioma / diagnosis. Humans. Image Processing, Computer-Assisted / methods. Liver Neoplasms / diagnosis. Magnetic Resonance Imaging / methods. Practice Guidelines as Topic. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • MedlinePlus Health Information. consumer health - Ultrasound.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19104714.001).
  • [ISSN] 1841-8724
  • [Journal-full-title] Journal of gastrointestinal and liver diseases : JGLD
  • [ISO-abbreviation] J Gastrointestin Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 15
  •  go-up   go-down


83. Jeong CW, Park YH, Shin CS, Kim HH: Synchronous bilateral laparoendoscopic single-site adrenalectomy. J Endourol; 2010 Aug;24(8):1301-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Abstract We present the first report of simultaneous laparoendoscopic single-site surgery (LESS) for bilateral primary aldosterone-producing adrenal adenomas.
  • A 40-year-old man with hypertension that was resistant to pharmacotherapy was shown to have bilateral aldosterone-producing adrenal adenomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20575688.001).
  • [ISSN] 1557-900X
  • [Journal-full-title] Journal of endourology
  • [ISO-abbreviation] J. Endourol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Orłowska J: Serrated polyps of the colorectum: histological classification and clinical significance. Pol J Pathol; 2010;61(1):8-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The serrated pathway encompassing hyperplastic aberrant crypt foci, hyperplastic polyps, sessile serrated polyps (adenomas), mixed polyps, and traditional serrated adenomas, with a meticulous review of their up-to-date histological classifications, is presented.
  • [MeSH-major] Adenoma. Colonic Polyps

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20496268.001).
  • [ISSN] 1233-9687
  • [Journal-full-title] Polish journal of pathology : official journal of the Polish Society of Pathologists
  • [ISO-abbreviation] Pol J Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


85. Magno S, Terribile D, Franceschini G, Fabbri C, Chiesa F, Di Leone A, Costantini M, Belli P, Masetti R: Early onset lactating adenoma and the role of breast MRI: a case report. J Med Case Rep; 2009;3:43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early onset lactating adenoma and the role of breast MRI: a case report.
  • INTRODUCTION: Lactating adenoma is a benign condition, representing the most prevalent breast lesion in pregnant women and during puerperium; in this paper, a case of a woman with lactating adenoma occurring during the first trimester of pregnancy is reported.
  • There have been no reports in the literature, according to our search, focusing on magnetic resonance imaging findings in cases of lactating adenomas.
  • CASE PRESENTATION: We report the case of a primiparous 30-year-old Caucasian woman, who noted an asymptomatic lump within her left breast during the 9th week of gestation, slightly increasing in size over the next few weeks.
  • On magnetic resonance imaging, performed in the first month after delivery, the lesion appeared as an ovoidal homogeneous mass, with regular margins and a significant contrast enhancement indicative of a giant adenoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 2005 Jan;58(1):87-9 [15623491.001]
  • [Cites] Radiology. 1998 Jan;206(1):271-4 [9423682.001]
  • [Cites] Cancer. 1994 Jul 1;74(1 Suppl):518-27 [8004627.001]
  • [Cites] Breast J. 2001 Sep-Oct;7(5):354-7 [11906446.001]
  • [Cites] Acta Cytol. 1991 Nov-Dec;35(6):676-86 [1659095.001]
  • [Cites] Acta Cytol. 1990 Jan-Feb;34(1):21-6 [2153326.001]
  • [Cites] Breast J. 2003 May-Jun;9(3):237-40 [12752635.001]
  • [Cites] Histopathology. 1993 May;22(5):481-5 [8344658.001]
  • (PMID = 19183446.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2647934
  •  go-up   go-down


86. Patel RS, Rose B, Bawdon H, Hong A, Lee CS, Fredericks S, Gao K, O'Brien CJ: Cyclin D1 and p16 expression in pleomorphic adenoma and carcinoma ex pleomorphic adenoma of the parotid gland. Histopathology; 2007 Nov;51(5):691-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclin D1 and p16 expression in pleomorphic adenoma and carcinoma ex pleomorphic adenoma of the parotid gland.
  • AIMS: To compare cyclin D1 and p16(ink4) (p16) expression in normal tissue, pleomorphic adenoma (PA) and carcinoma ex pleomorphic adenoma (CXPA) of the parotid gland.
  • Cyclin D1 was more likely to be expressed in the malignant components of CXPA than in the benign components of PA (50% versus 31% and 31%, respectively), but the trend was not statistically significant.
  • [MeSH-major] Adenoma, Pleomorphic / metabolism. Carcinoma / metabolism. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Cyclins / metabolism. Parotid Gland / metabolism. Parotid Neoplasms / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17927591.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cyclin D; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Cyclins
  •  go-up   go-down


87. Shaukat A, Scouras N, Schünemann HJ: Role of supplemental calcium in the recurrence of colorectal adenomas: a metaanalysis of randomized controlled trials. Am J Gastroenterol; 2005 Feb;100(2):390-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of supplemental calcium in the recurrence of colorectal adenomas: a metaanalysis of randomized controlled trials.
  • BACKGROUND: Colorectal adenomas are neoplastic growths that are important targets for chemoprevention.
  • However, the role of calcium supplementation for preventing recurrence of adenomas is controversial.
  • We performed a systematic review and meta-analysis to study the role of calcium supplementation in preventing recurrence of adenomas.
  • RESULTS: We identified three trials including 1,485 subjects with previously removed adenomas who were randomized to calcium versus placebo supplementation.
  • The study endpoint was recurrence of adenomas at the end of 3-4 yr in 1,279 patients who completed the trials.
  • We found that the recurrence of adenomas was significantly lower in subjects randomized to calcium supplementation (RR: 0.80, CI: 0.68, 0.93; p-value = 0.004).
  • CONCLUSIONS: This systematic review and meta-analysis suggest that calcium supplementation prevents recurrent colorectal adenomas.
  • [MeSH-major] Adenoma / prevention & control. Calcium / administration & dosage. Chemoprevention. Colorectal Neoplasms / prevention & control. Dietary Supplements. Neoplasm Recurrence, Local / prevention & control

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Dietary Supplements.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • PubMed Health. DARE review .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Gastroenterol. 2005 Feb;100(2):395-6 [15667498.001]
  • (PMID = 15667497.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] United States
  • [Chemical-registry-number] SY7Q814VUP / Calcium
  •  go-up   go-down


88. Naço M, Celiku E, Llukaçaj A, Shehaj J, Kameniku R: Toxic adenoma of the thyroid gland and Wolff-Parkinson-White syndrome. Hippokratia; 2009 Apr;13(2):116-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toxic adenoma of the thyroid gland and Wolff-Parkinson-White syndrome.
  • We report the case of a 17-year-old girl with toxic adenoma scheduled for surgery right lobectomy and isthmectomy of thyroid gland.
  • In this case report we discuss the role of induction of anesthesia and presence of toxic adenoma in a patient with WPW.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Geriatr Soc. 1996 Jan;44(1):44-9 [8537589.001]
  • [Cites] J Clin Invest. 1995 Sep;96(3):1216-20 [7657794.001]
  • [Cites] J Am Coll Cardiol. 1994 Jan;23(1):107-16 [8277067.001]
  • [Cites] N Engl J Med. 1991 Jun 6;324(23):1605-11 [2030716.001]
  • [Cites] J Clin Endocrinol Metab. 1988 Mar;66(3):570-9 [2832439.001]
  • [Cites] N Engl J Med. 2001 Jun 14;344(24):1823-31 [11407343.001]
  • [Cites] Ann Intern Med. 1984 Oct;101(4):488-90 [6476634.001]
  • [Cites] Prog Cardiovasc Dis. 1978 Jan-Feb;20(4):285-327 [146210.001]
  • [Cites] J Pharmacol Exp Ther. 1978 Nov;207(2):532-8 [712635.001]
  • [Cites] Circulation. 1971 Apr;43(4):520-7 [5573385.001]
  • [Cites] Crit Care Med. 2002 Jan;30(1):142-56 [11902255.001]
  • [Cites] J Am Coll Cardiol. 1985 Jan;5(1):130-5 [3964800.001]
  • (PMID = 19561784.001).
  • [ISSN] 1790-8019
  • [Journal-full-title] Hippokratia
  • [ISO-abbreviation] Hippokratia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Other-IDs] NLM/ PMC2683455
  • [Keywords] NOTNLM ; Wolff-Parkinson-White syndrome / accessory pathway / congenital heart defect / hyper functioning solitary nodule / preexcitation / radio-frequency ablation / surgical ablation / toxic adenoma
  •  go-up   go-down


89. Sato Y, Osaka H, Harada K, Sasaki M, Nakanuma Y: Intraductal tubular neoplasm of the common bile duct. Pathol Int; 2010 Jul;60(7):516-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal tubular neoplasm of the common bile duct.
  • In this report, a rare case of intraductal tubular neoplasm (ITN) arising in the common bile duct is presented.
  • Histology of the lesion revealed tubular neoplasm, composed of an admixture of tubular glands resembling pyloric gland adenoma with minimal atypia (low-grade tubular adenoma), and those resembling intestinal type tubular adenoma (high-grade tubular adenoma).
  • On immunostaining low-grade tubular adenoma was positive for MUC5AC and MUC6, and negative for MUC2 and cytokeratin (CK) 20, while high-grade tubular adenoma and carcinoma in situ were positive for MUC2 and CK20, and negative for MUC5AC.
  • [MeSH-major] Adenoma / pathology. Bile Duct Neoplasms / pathology. Common Bile Duct / pathology

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20594273.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


90. Matusiewicz M, Krzystek-Korpacka M, Diakowska D, Grabowski K, Augoff K, Blachut K, Paradowski L, Kustrzeba-Wojcicka I, Piast M, Banas T: Serum sulfatase activity is more elevated in colonic adenomas than cancers. Int J Colorectal Dis; 2008 Apr;23(4):383-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum sulfatase activity is more elevated in colonic adenomas than cancers.
  • BACKGROUND AND AIMS: Elucidation of molecular basis of the adenomatous polyps (AP) and colorectal cancer (CRC) development is crucial for their prevention, early detection, and treatment.
  • Because the majority of CRCs arise from AP, the aim of our studies was the investigation of sulfatase activity in adenomas and adenocarcinomas and verification of possible usefulness of sulfatase activity determination as an indicator of the presence and discrimination between adenomas and carcinomas.
  • The activity was more elevated in adenomas (149; 128-173 U) than in cancers (103; 90-112 U).
  • It increased with number of adenomas and tended to decrease with tumor progression.
  • Sulfatase upregulation in majority of adenomas and their correlation tendencies warrants reconsideration of sulfatase determination as a possible diagnostic tool.
  • [MeSH-major] Adenomatous Polyposis Coli / enzymology. Colorectal Neoplasms / enzymology. Sulfotransferases / blood
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Colorimetry. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Severity of Illness Index

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Chim Acta. 1991 Dec 31;204(1-3):69-77 [1687888.001]
  • [Cites] Br J Cancer. 2003 May 6;88(9):1445-52 [12778076.001]
  • [Cites] Neoplasma. 2002;49(1):10-5 [12044053.001]
  • [Cites] J Pediatr. 1975 Apr;86(4):574-6 [805221.001]
  • [Cites] Clin Biochem. 2004 Aug;37(8):673-8 [15302609.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):568-73 [11805315.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2005;6:355-79 [16124866.001]
  • [Cites] Cancer. 1975 Dec;36(6 Suppl):2337-45 [1212650.001]
  • [Cites] Mol Cancer. 2005 Apr 07;4(1):14 [15817123.001]
  • [Cites] Oncol Rep. 2005 Dec;14(6):1583-8 [16273260.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4833-8 [15051888.001]
  • [Cites] Pol Merkur Lekarski. 2004 Sep;17(99):252-4 [15628052.001]
  • [Cites] J Biol Chem. 2003 Jun 20;278(25):23107-17 [12686563.001]
  • [Cites] J Cell Biochem. 2005 Dec 1;96(5):897-905 [16149080.001]
  • [Cites] Gastroenterology. 2003 Feb;124(2):544-60 [12557158.001]
  • [Cites] Cancer Lett. 2001 May 10;166(1):95-101 [11295292.001]
  • [Cites] Eur J Cancer. 2005 Feb;41(3):365-79 [15691635.001]
  • [Cites] J Biol Chem. 2002 Dec 20;277(51):49175-85 [12368295.001]
  • [Cites] World J Gastroenterol. 1998 Feb;4(1):52-54 [11819231.001]
  • (PMID = 18193432.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.8.2.- / SULF1 protein, human; EC 2.8.2.- / Sulfotransferases
  •  go-up   go-down


91. Lee SY, Chung H, Devaraj B, Iwaizumi M, Han HS, Hwang DY, Seong MK, Jung BH, Carethers JM: Microsatellite alterations at selected tetranucleotide repeats are associated with morphologies of colorectal neoplasias. Gastroenterology; 2010 Nov;139(5):1519-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We evaluated tumor samples from a cohort of patients that had 24 adenomas and 84 colorectal cancers.
  • EMAST were analyzed after DNA microdissection of matched normal and tumor samples using the polymorphic tetranucleotide microsatellite markers MYCL1, D9S242, D20S85, D8S321, and D20S82; data were compared with clinical and pathology findings.
  • RESULTS: Moderately differentiated adenocarcinomas and poorly differentiated adenocarcinomas had higher frequencies of EMAST (56.9% and 40.0%, respectively) than well-differentiated adenocarcinomas (12.5%) or adenomas (33.3%) (P = .040).
  • CONCLUSIONS: EMAST is acquired during progression of adenoma and well-differentiated carcinomas to moderately and poorly differentiated carcinomas; it correlates with nuclear heterogeneity for hMSH3.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
  • [Cites] BJU Int. 2007 May;99(5):1031-5 [17233803.001]
  • [Cites] J Gastrointest Surg. 2010 Oct;14(10):1521-8 [20844976.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2008 Jul;18(3):581-93, xi [18674705.001]
  • [Cites] Cancer Res. 2000 May 1;60(9):2488-91 [10811129.001]
  • [Cites] Int J Cancer. 2001 Jan 15;91(2):200-4 [11146445.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7444-8 [11606378.001]
  • [Cites] Am J Physiol Cell Physiol. 2002 Jul;283(1):C148-54 [12055083.001]
  • [Cites] Oncogene. 2002 Jul 25;21(32):4894-9 [12118368.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1608-14 [12670912.001]
  • [Cites] Oncogene. 2003 Nov 27;22(54):8699-706 [14647464.001]
  • [Cites] Cancer Res. 1996 Mar 15;56(6):1237-40 [8640805.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] Int J Cancer. 2006 May 15;118(10):2509-13 [16380996.001]
  • [Cites] J Mol Med (Berl). 2006 Apr;84(4):329-33 [16416315.001]
  • [Cites] J Mol Med (Berl). 2006 Oct;84(10):833-41 [16924473.001]
  • [Cites] Cancer Res. 2008 Oct 15;68(20):8465-72 [18922920.001]
  • [Cites] Gastroenterology. 2008 Oct;135(4):1079-99 [18773902.001]
  • [Cites] J Exp Clin Cancer Res. 2008;27:88 [19116039.001]
  • [Cites] Oncol Rep. 2010 Feb;23(2):551-61 [20043121.001]
  • [Cites] Fam Cancer. 2008;7(1):41-52 [17636426.001]
  • (PMID = 20708618.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK067287; United States / NCI NIH HHS / CA / CA132384; United States / NCI NIH HHS / CA / U54 CA132384; United States / NIDDK NIH HHS / DK / R24 DK080506; United States / NCI NIH HHS / CA / CA132379; United States / NIDDK NIH HHS / DK / DK067287; United States / NCI NIH HHS / CA / U54 CA132379; United States / NIDDK NIH HHS / DK / DK080506
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / MSH3 protein, human
  • [Other-IDs] NLM/ NIHMS229907; NLM/ PMC2967646
  •  go-up   go-down


92. Hindié E, Ugur O, Fuster D, O'Doherty M, Grassetto G, Ureña P, Kettle A, Gulec SA, Pons F, Rubello D, Parathyroid Task Group of the EANM: 2009 EANM parathyroid guidelines. Eur J Nucl Med Mol Imaging; 2009 Jul;36(7):1201-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary hyperparathyroidism is an endocrine disorder with high prevalence, typically caused by a solitary parathyroid adenoma, less frequently (about 15%) by multiple parathyroid gland disease (MGD) and rarely (1%) by parathyroid carcinoma.
  • Patients with MGD may have a double adenoma or hyperplasia of three or all four parathyroid glands.
  • Scintigraphy should also report on thyroid nodules that may cause confusion with a parathyroid adenoma or require concurrent surgical resection.
  • The guidelines also discuss aspects related to radio-guided surgery of hyperparathyroidism and imaging of chronic kidney disease patients with secondary hyperparathyroidism.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2009 Feb;94(2):335-9 [19193908.001]
  • [Cites] Radiology. 2000 Feb;214(2):393-402 [10671586.001]
  • [Cites] PET Clin. 2007 Jul;2(3):385-93 [27158018.001]
  • [Cites] Arch Pathol Lab Med. 2008 Aug;132(8):1251-62 [18684024.001]
  • [Cites] J Nucl Med. 1998 Jun;39(6):1111-4 [9627355.001]
  • [Cites] Am J Surg. 1996 Dec;172(6):633-6 [8988665.001]
  • [Cites] Head Neck. 2008 Apr;30(4):509-17 [18059012.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 Apr;33(4):467-73 [16404597.001]
  • [Cites] Lancet. 1997 Apr 26;349(9060):1233-8 [9130957.001]
  • [Cites] Eur J Nucl Med. 2000 Sep;27(9):1300-4 [11007510.001]
  • [Cites] J Nucl Med. 2007 Jul;48(7):1084-9 [17574983.001]
  • [Cites] Surgery. 2006 Nov;140(5):837-8 [17084734.001]
  • [Cites] Eur J Nucl Med. 1995 Jun;22(6):556-8 [7556303.001]
  • [Cites] Nucl Med Commun. 2003 Feb;24(2):133-40 [12548037.001]
  • [Cites] J Nucl Med. 1998 Oct;39(10):15N, 24N [9776261.001]
  • [Cites] Endocr Pract. 2005 Jan-Feb;11(1):49-54 [16033736.001]
  • [Cites] J Nucl Med. 1992 Oct;33(10 ):1801-7 [1328564.001]
  • [Cites] Surgery. 1997 Mar;121(3):287-94 [9092129.001]
  • [Cites] J Nucl Med. 1992 Mar;33(3):313-8 [1531500.001]
  • [Cites] Panminerva Med. 2002 Jun;44(2):99-105 [12032427.001]
  • [Cites] Nephrol Dial Transplant. 1997 Jan;12 (1):97-100 [9027781.001]
  • [Cites] J Nucl Med. 2003 Sep;44(9):1443-58 [12960191.001]
  • [Cites] Radiology. 2001 Mar;218(3):916-7 [11230677.001]
  • [Cites] J Nucl Med. 1998 Jun;39(6):1100-5 [9627353.001]
  • [Cites] J Nucl Med. 1997 Jun;38(6):831-4 [9189124.001]
  • [Cites] Surgery. 1993 Dec;114(6):1011-8 [8256204.001]
  • [Cites] Nucl Med Commun. 2006 Dec;27(12):977-87 [17088684.001]
  • [Cites] Radiology. 1997 Jul;204(1):221-8 [9205251.001]
  • [Cites] J Nucl Med. 1996 Nov;37(11):1809-15 [8917180.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Jan;81(1):346-52 [8550776.001]
  • [Cites] Semin Ultrasound CT MR. 1995 Aug;16(4):279-95 [7576775.001]
  • [Cites] Lancet. 1999 Jun 26;353(9171):2200-4 [10392985.001]
  • [Cites] Surgery. 1986 Jun;99(6):643-51 [3715716.001]
  • [Cites] Nucl Med Commun. 1989 Nov;10 (11):791-4 [2532313.001]
  • [Cites] J Nucl Med. 2005 Feb;46(2):248-52 [15695783.001]
  • [Cites] Clin Med Res. 2004 Feb;2(1):55-8 [15931335.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Mar;87(3):1024-9 [11889156.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2007 May;34(5):796-8 [17406866.001]
  • [Cites] Am Surg. 2003 Aug;69(8):720-5 [12953832.001]
  • [Cites] Ann Intern Med. 1991 Apr 1;114(7):593-7 [1900404.001]
  • [Cites] Minerva Endocrinol. 2008 Jun;33(2):95-104 [18268473.001]
  • [Cites] Surgery. 1984 Jan;95(1):14-21 [6691181.001]
  • [Cites] Arch Surg. 2002 Sep;137(9):1055-9 [12215160.001]
  • [Cites] Arch Surg. 2000 Dec;135(12 ):1461-8 [11115353.001]
  • [Cites] World J Surg. 2008 May;32(5):774-81; discussion 782-3 [18335276.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 Apr;33(4):453-9 [16435115.001]
  • [Cites] Am J Kidney Dis. 2008 Sep;52(3):519-30 [18514987.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2008 Mar;35(3):637-43 [17960377.001]
  • [Cites] Otolaryngol Head Neck Surg. 2006 Feb;134(2):316-20 [16455383.001]
  • [Cites] Arch Surg. 2002 Aug;137(8):917-22; discussion 922-3 [12146990.001]
  • [Cites] Nucl Med Commun. 2004 Nov;25(11):1089-93 [15577586.001]
  • [Cites] J Nucl Med. 2004 Jan;45(1):40-8 [14734671.001]
  • [Cites] J Nucl Med. 2008 Dec;49(12):2012-7 [18997051.001]
  • [Cites] Eur J Endocrinol. 1998 Aug;139(2):195-7 [9724076.001]
  • [Cites] Environ Health Perspect. 1997 Dec;105 Suppl 6:1403-9 [9467052.001]
  • [Cites] Surgery. 1997 Dec;122(6):998-1003; discussion 1003-4 [9426412.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Feb;30(2):189-2 [12643287.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Aug;57(2):241-9 [12153604.001]
  • [Cites] J Nucl Med. 1996 Nov;37(11):1773-8 [8917173.001]
  • [Cites] Eur J Nucl Med. 1994 Jan;21(1):17-22 [8088281.001]
  • [Cites] Surgery. 1999 Dec;126(6):1023-8; discussion 1028-9 [10598183.001]
  • [Cites] J Nucl Med. 2006 Jul;47(7):1227-34 [16818960.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Jan;80(1):302-7 [7829631.001]
  • [Cites] J Am Coll Surg. 2002 Jul;195(1):19-22 [12113540.001]
  • [Cites] Radiology. 1994 Jul;192(1):280 [8208955.001]
  • [Cites] Clin Nucl Med. 2000 Jul;25(7):527-31 [10885694.001]
  • [Cites] World J Surg. 2006 Jan;30(1):76-83 [16369710.001]
  • [Cites] Br J Surg. 1982 May;69(5):244-7 [7074331.001]
  • [Cites] Arch Surg. 1989 Aug;124(8):911-4; discussion 914-5 [2757503.001]
  • [Cites] J Bone Miner Res. 2002 Nov;17 Suppl 2:N37-43 [12412776.001]
  • [Cites] Arch Surg. 2002 Aug;137(8):967-70 [12147000.001]
  • [Cites] Br J Surg. 1996 Jul;83(7):989-91 [8813796.001]
  • [Cites] Ann Surg Oncol. 2008 Oct;15(10):2653-60 [18677536.001]
  • [Cites] J Nucl Med. 2003 Jun;44(6):904-8 [12791817.001]
  • [Cites] Eur J Nucl Med. 2001 Sep;28(9):1409-20 [11585302.001]
  • [Cites] Radiology. 1998 Apr;207 (1):207-13 [9580138.001]
  • [Cites] Adv Anat Pathol. 2005 Mar;12(2):53-61 [15731573.001]
  • [Cites] J Nucl Med. 1991 Aug;32(8):1627-39 [1869992.001]
  • [Cites] Nucl Med Commun. 1995 Jul;16(7):522-33 [7478389.001]
  • [Cites] Eur J Endocrinol. 2003 Jul;149(1):7-15 [12824860.001]
  • [Cites] J Nucl Med. 1983 May;24(5):438-41 [6842292.001]
  • [Cites] Radiology. 1996 Oct;201(1):85-91 [8816526.001]
  • [Cites] Minerva Endocrinol. 2001 Mar;26(1):3-12 [11323562.001]
  • [Cites] J Nucl Med Technol. 2007 Sep;35(3):135-9 [17702904.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Nov;83(11):3867-71 [9814460.001]
  • [Cites] Eur J Nucl Med. 1996 Jun;23 (6):693-6 [8662105.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2007 Dec;133(12 ):1235-9 [18086965.001]
  • (PMID = 19471928.001).
  • [ISSN] 1619-7089
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Practice Guideline
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 971Z4W1S09 / Technetium Tc 99m Sestamibi; A0730CX801 / Sodium Pertechnetate Tc 99m
  •  go-up   go-down


93. Lin MX, Wen ZF, Feng ZY, He D: [Expression and significance of Bmi-1 and Ki67 in colorectal carcinoma tissues]. Ai Zheng; 2008 Dec;27(12):1321-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Protein expressions of Bmi-1 and Ki67 in sixty CRC, 30 adenomas and 20 normal colorectal mucosal tissues were detected using immunohistochemistry.
  • RESULTS: The expression rates of Bmi-1 and Ki67 were 25.0%, 6.7%, 0% and 18.3%, 3.3% and 0% in CRC, adenomas and normal colorectal mucosal tissues, respectively.
  • The expression of Bim-1 and Ki67 were significantly higher in CRC than in adenomas and normal colorectal mucosal tissues (P<0.05).
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adenoma / metabolism. Adenoma / pathology. Adult. Age Factors. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Intestinal Mucosa / metabolism. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Polycomb Repressive Complex 1. Prognosis. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19080002.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / BMI1 protein, human; 0 / Ki-67 Antigen; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins; 0 / Repressor Proteins; EC 6.3.2.19 / Polycomb Repressive Complex 1
  •  go-up   go-down


94. Shureiqi I, Wu Y, Chen D, Yang XL, Guan B, Morris JS, Yang P, Newman RA, Broaddus R, Hamilton SR, Lynch P, Levin B, Fischer SM, Lippman SM: The critical role of 15-lipoxygenase-1 in colorectal epithelial cell terminal differentiation and tumorigenesis. Cancer Res; 2005 Dec 15;65(24):11486-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We examined whether this shift occurs in vitro in the human colon cancer cell line Caco-2 in association with the loss of terminal differentiation and apoptosis, or in vivo during the formation of colorectal adenomas in patients with familial adenomatous polyposis (FAP).
  • In FAP patients, 15-LOX-1 expression and activity were significantly down-regulated in adenomas (compared with paired nonneoplastic epithelial mucosa), whereas 5-LOX and 15-LOX-2 protein expressions and enzymatic activities were not.
  • We conducted a validation study with immunohistochemical testing in a second group of FAP patients; 15-LOX-1 expression was down-regulated in colorectal adenomas (compared with nonneoplastic epithelial mucosa) in 87% (13 of 15) of this group.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FEBS Lett. 2000 Feb 11;467(2-3):341-7 [10675566.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Feb 24;268(3):778-83 [10679282.001]
  • [Cites] N Engl J Med. 2000 Jun 29;342(26):1946-52 [10874062.001]
  • [Cites] J Natl Cancer Inst. 2000 Jul 19;92(14):1136-42 [10904086.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):6846-50 [11156377.001]
  • [Cites] Cancer Res. 2001 Jan 15;61(2):497-503 [11212240.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4879-84 [11406566.001]
  • [Cites] Cancer Res. 2001 Sep 1;61(17):6307-12 [11522616.001]
  • [Cites] Anal Biochem. 2001 Oct 15;297(2):183-90 [11673886.001]
  • [Cites] Cell. 2002 Jan 25;108(2):153-64 [11832206.001]
  • [Cites] Cancer Res. 2002 Feb 15;62(4):1178-83 [11861401.001]
  • [Cites] Cancer Res. 2002 May 1;62(9):2721-7 [11980674.001]
  • [Cites] Nucleic Acids Res. 2001 May 1;29(9):e45 [11328886.001]
  • [Cites] Carcinogenesis. 2003 Feb;24(2):243-7 [12584173.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9968-73 [12909723.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6170-3 [14559799.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2004 Jan;70(1):7-15 [14643174.001]
  • [Cites] Prostaglandins Other Lipid Mediat. 2004 Jan;73(1-2):111-22 [15165036.001]
  • [Cites] J Biol Chem. 2004 Jul 2;279(27):28028-35 [15123685.001]
  • [Cites] J Biol Chem. 1990 Mar 25;265(9):5113-20 [2318885.001]
  • [Cites] Cancer Res. 1994 Jun 15;54(12):3288-93 [8205551.001]
  • [Cites] J Biol Chem. 1998 Aug 21;273(34):21569-77 [9705287.001]
  • [Cites] Carcinogenesis. 1999 Oct;20(10):1985-95 [10506115.001]
  • [Cites] Nat Rev Cancer. 2005 Mar;5(3):231-7 [15738985.001]
  • (PMID = 16357157.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K07 CA086970; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / K07 CA86970; United States / NCI NIH HHS / CA / P30 CA16672
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Linoleic Acids; 0 / RNA, Messenger; 5204-88-6 / 13-hydroxy-9,11-octadecadienoic acid; EC 1.13.11.33 / ALOX15B protein, human; EC 1.13.11.33 / Arachidonate 15-Lipoxygenase; EC 1.13.11.34 / Arachidonate 5-Lipoxygenase
  • [Other-IDs] NLM/ NIHMS5001; NLM/ PMC1564070
  •  go-up   go-down


95. Kobayashi T: Long-term results of stereotactic gamma knife radiosurgery for pituitary adenomas. Specific strategies for different types of adenoma. Prog Neurol Surg; 2009;22:77-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of stereotactic gamma knife radiosurgery for pituitary adenomas. Specific strategies for different types of adenoma.
  • Long-term results of gamma knife radiosurgery for pituitary adenomas are presented and treatment strategies for different adenoma types are discussed.
  • Two hundred and sixty-seven patients with pituitary adenoma have been treated by gamma knife radiosurgery during the past 12 years.
  • There were 131 cases of nonfunctioning and 136 cases of functioning adenomas, in which 71 GH-producing, 33 PRL-producing and 32 ACTH-producing adenomas were included.
  • Micro- and small adenomas could be cured by gamma knife radiosurgery alone.
  • Surgical or chemical debulking was necessary before radiosurgery for a large tumor with extrasellar extension.
  • Nonfunctioning adenomas showed higher control rates than functioning adenomas even with lower dose treatment.
  • Cushing disease showed the best response because of the smallest tumor size with the highest dose treatment.
  • The rate of hormone normalization was also high in Cushing disease but lower in prolactinoma and lowest in acromegaly.
  • High-dose treatment was necessary for functioning adenomas to control tumor growth and oversecretion of hormones.
  • In conclusion, gamma knife radiosurgery was effective and safe for the treatment of pituitary adenomas.
  • However, the treatment strategies should be specific to each adenoma type according to the radiosensitivity, chemosensitivity and biological nature of the tumor.
  • [MeSH-major] ACTH-Secreting Pituitary Adenoma / surgery. Acromegaly / surgery. Adenoma / surgery. Radiosurgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Child. Female. Follow-Up Studies. Growth Hormone-Secreting Pituitary Adenoma / pathology. Growth Hormone-Secreting Pituitary Adenoma / surgery. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Patient Satisfaction. Pituitary ACTH Hypersecretion / pathology. Pituitary ACTH Hypersecretion / surgery. Prolactinoma / pathology. Prolactinoma / surgery. Treatment Outcome. Young Adult

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18948721.001).
  • [ISSN] 0079-6492
  • [Journal-full-title] Progress in neurological surgery
  • [ISO-abbreviation] Prog Neurol Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


96. Takahashi H, Hosono K, Uchiyama T, Sugiyama M, Sakai E, Endo H, Maeda S, Schaefer KL, Nakagama H, Nakajima A: PPARgamma Ligand as a Promising Candidate for Colorectal Cancer Chemoprevention: A Pilot Study. PPAR Res; 2010;2010
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Previously, CRC and adenoma were used as a target for chemopreventive agents, but it needs a long time to evaluate, however, ACF can be a surrogate marker of CRC even for a brief period.
  • Twenty-nine patients were divided into two groups, 20 were in the endoscopically normal control group and 9 were in the pioglitazone (15 mg/day) group, and ACF and adenoma were examined before and after 1-month treatment.
  • The number of ACF was significantly decreased (5.8 +/- 1.1 to 3.3 +/- 2.3) after 1 month of pioglitazone treatment, however, there was no significant change in the number of crypts/ACF or in the number and size of adenomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20814432.001).
  • [ISSN] 1687-4765
  • [Journal-full-title] PPAR research
  • [ISO-abbreviation] PPAR Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2929500
  •  go-up   go-down


97. Chen H, Pruhs Z, Starling JR, Mack E: Intraoperative parathyroid hormone testing improves cure rates in patients undergoing minimally invasive parathyroidectomy. Surgery; 2005 Oct;138(4):583-7; discussion 587-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • From January 1990 to June 2004, there were 345 consecutive patients with 1 degrees HPT and positive localization studies for a single parathyroid adenoma who were candidates for minimally invasive parathyroidectomy.
  • In contrast, among 188 group 2 patients, 170 (90%) had resection of a single parathyroid adenoma, a greater than 50% decrease in iPTH levels, and were cured.
  • Of these 18 patients, 9 had double adenomas and 9 had 3- or 4-gland hyperplasia.
  • [MeSH-minor] Adenoma / complications. Humans. Hyperplasia. Middle Aged. Parathyroid Glands / pathology. Parathyroid Neoplasms / complications. Retrospective Studies. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16269285.001).
  • [ISSN] 0039-6060
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Parathyroid Hormone
  •  go-up   go-down


98. Jaquet P, Gunz G, Saveanu A, Dufour H, Taylor J, Dong J, Kim S, Moreau JP, Enjalbert A, Culler MD: Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy. Eur J Endocrinol; 2005 Jul;153(1):135-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy.
  • OBJECTIVE: This study compared the potency of a somatostatin receptor (sstr)2-sstr5 analog, BIM-23244, of an sstr2-dopamine D2 receptor (sstr2-DAD2) molecule, BIM-23A387 and of new somatostatin-dopamine chimeric molecules with differing, enhanced affinities for sstr2, sstr5 and DAD2, BIM-23A758, BIM-23A760 and BIM-23A761, to suppress GH and prolactin (PRL) from 18 human GH adenomas that are partially responsive to octreotide or lanreotide.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. DOPAMINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15994755.001).
  • [ISSN] 0804-4643
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / BIM 23A760; 0 / BIM-23244; 0 / BIM-23A761; 0 / RNA, Messenger; 0 / Receptors, Dopamine D2; 0 / Receptors, Somatostatin; 0 / Recombinant Fusion Proteins; 0 / somatostatin receptor 2; 0 / somatostatin receptor 5; 12629-01-5 / Human Growth Hormone; 51110-01-1 / Somatostatin; 9002-62-4 / Prolactin; RWM8CCW8GP / Octreotide; VTD58H1Z2X / Dopamine
  •  go-up   go-down


99. Aiad HA, Kandil MA, Asaad NY, El-Kased AM, El-Goday SF: Galectin-3 immunostaining in cytological and histopathological diagnosis of thyroid lesions. J Egypt Natl Canc Inst; 2008 Mar;20(1):36-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Galectin-3 is a human lectin linked to malignant transformation in different organs including thyroid gland.
  • We aimed to evaluate the diagnostic role of galectin-3 in differentiating benign from malignant thyroid lesions in cytological and histological samples.
  • MATERIAL AND METHODS: This study included a total of 79 cases; 19 multinodular goiter (MNG), 19 follicular adenoma (FA), 13 follicular carcinoma (FTC) and 28 papillary carcinoma (PTC).
  • Prospective analysis: There were five benign, six malignant and 17 indeterminate cytology cases.
  • Galectin-3 immunostaining was able to detect the benign nature of 11/17 indeterminate cytology.
  • CONCLUSION: We suggest Galectin-3 as a supplementary immunostaining in histological diagnosis of difficult thyroid follicular lesions and in preoperative evaluation of indeterminate thyroid cytology to avoid unnecessary aggressive surgical interference in benign lesions.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19847280.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / Galectin 3
  •  go-up   go-down


100. Plouin PF, Gimenez-Roqueplo AP, Bertagna X: [COMETE, a network for the study and management of hypersecreting adrenal tumors]. Bull Acad Natl Med; 2008 Jan;192(1):73-82; discussion 83-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with adrenal tumors are at risk of the consequences of tumor growth (including metastasis) and of hormone hypersecretion.
  • Pheochromocytomas and paragangliomas arise from the adrenal medulla and produce catecholamines; they may be benign or malignant, and sporadic or familial.
  • Adrenal adenomas and carcinomas arise from the adrenal cortex.
  • This implies - in cross-sectional studies: collecting adrenal tumors, maintaining a collection of tumor and leukocyte DNA samples, keeping a computerized record of relevant biological and clinical data, and distributing biological samples and bioclinical information anonymously to collaborating research laboratories; in prospective studies: ensuring indefinite follow-up of patients with tumors at risk of malignancy or recurrence, which means establishing and maintaining a cohort of patients with large adrenocortical tumors or carcinomas anda cohort of patients with pheochromocytomas or paragangliomas.
  • [MeSH-major] Adrenal Gland Neoplasms / metabolism. Societies, Medical / organization & administration
  • [MeSH-minor] Adenoma / metabolism. France. Humans. Pheochromocytoma / metabolism. Research

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18663983.001).
  • [ISSN] 0001-4079
  • [Journal-full-title] Bulletin de l'Académie nationale de médecine
  • [ISO-abbreviation] Bull. Acad. Natl. Med.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down






Advertisement